<?xml version='1.0' encoding='UTF-8'?>
<chapter id="ch0101">
    <title>82 Specimen Collection, Transport, and Processing: Virology</title>
    <sect1 id="ch0101s0001">
      <title>82 Specimen Collection, Transport, and Processing: Virology</title>
      <anchor id="ch0101s0001a0001"/>
      <anchor id="ch0101s0001a0002"/>
      <para id="ch0101s0001p0001" role="chapterAuthor">JAMES J. DUNN AND BENJAMIN A. PINSKY</para>
      <para id="ch0101s0001p0002">Given that laboratory data significantly influence medical diagnoses, it is critical that all phases of testing (pre-, intra-, and postanalytical) be approached systematically to ensure the accuracy of results and to detect and correct potential errors. The preanalytical phase is often the most vulnerable part of the testing process and accounts for the majority of errors in laboratory diagnostics (<link linkend="ch0101s0014s0003li0001">1</link>). Preanalytical steps for viral diagnostics involving specimen selection, collection, transport, and processing are described in this chapter, as well as details for collection of specific sample types. While these recommendations are general guidelines, laboratories must also follow manufacturers’ instructions for testing of samples with commercially available kits and reagents.</para>
      <para id="ch0101s0001p0003">Preanalytical variables should be controlled to maintain specimen integrity. Therefore, it is important for the laboratory to make available to all specimen-collecting areas within the institution, or other locations submitting samples, a comprehensive manual of tests available, with indications for appropriate use and specimen collection, which details the appropriate (i) specimen types for specific clinical syndromes (<anchor id="ch0101s0001a0003"/><link linkend="ch0101s0001s0002a0006">Table 1</link>), (ii) collection devices/containers and transport media when indicated, (iii) collection techniques, (iv) volume of specimen required, (v) specimen labeling, (vi) transport times and storage conditions, and (vii) test performance characteristics, if available (<link linkend="ch0101s0014s0003li0002">2</link>).</para>
      <sect2 id="ch0101s0001s0001">
        <title>SPECIMEN SELECTION</title>
        <anchor id="ch0101s0001s0001a0001"/>
        <anchor id="ch0101s0001s0001a0002"/>
        <para id="ch0101s0001s0001p0001">Viruses infecting humans cause a wide range of diseases. Signs and symptoms of infection largely influence which specimens are collected for virus testing. Additional factors to be considered are epidemiologic details (e.g., travel, exposures, and season) and the patient’s immune status. It is important to recognize that viruses differ in their pathogenic mechanisms, their ability to disseminate from the primary site of infection, and the organ systems they infect. Generally, specimen selection is guided by the test best suited to establish a particular diagnosis (summarized in<ulink url="ch0103#ch0103s0001">chapter 84</ulink> of this <emphasis>Manual</emphasis>). The diagnosis of certain illnesses requires a basic understanding of viral pathogenesis, organ involvement, and viral epidemiology to determine the appropriate specimen(s) and tests. Specimen selection based on suspicion of a particular virus may be complicated by the fact that similar clinical syndromes can be caused by many different viruses (<link linkend="ch0101s0001s0002a0006">Table 1</link>). If only the specimens needed to detect a specific virus are collected, other important etiologies may be missed.</para>
        <para id="ch0101s0001s0001p0002">Depending on the anatomic site and means of collection, specimens are either nonsterile (i.e., contaminated with bacteria and/or fungi) or sterile. This determines the extent of specimen processing that occurs prior to viral culture, since bacteria and fungi grow rapidly in nutrient-rich cell culture systems. Non-culture-based test methods are less impacted by this distinction. Sterile specimens (e.g., blood, cerebrospinal fluid [CSF], and tissue) are obtained from sites that are free of microorganisms in the absence of infection, and there is no contact with nonsterile sites during the collection process. Nonsterile specimens (e.g., upper respiratory tract, skin, lower genital tract, and stool) are obtained from sites that contain normal microbiota, or they are obtained from sterile sites but contact with nonsterile sites is unavoidable during specimen collection (e.g., sputum and voided urine).</para>
      </sect2>
      <sect2 id="ch0101s0001s0002">
        <title>SPECIMEN COLLECTION</title>
        <anchor id="ch0101s0001s0002a0001"/>
        <anchor id="ch0101s0001s0002a0002"/>
        <para id="ch0101s0001s0002p0001">Since no single diagnostic approach may be optimal for detecting every possible virus in a clinical situation, it may be necessary to utilize a combination of test methods and/or to collect a number of different sample types and/or longitudinal samples for testing to yield the most medically useful information (<link linkend="ch0101s0014s0003li0002">2</link>). These are particularly important considerations in the era of metagenomic pathogen identification, given that unbiased sequencing methods have not yet been shown to be as sensitive as targeted approaches (<link linkend="ch0101s0014s0003li0003">3</link>, <link linkend="ch0101s0014s0003li0004">4</link>). To optimize viral diagnosis, specimens should be collected as soon as possible after the onset of symptoms. For many viral infections in otherwise healthy and immunocompetent individuals, the likelihood of obtaining positive results is generally greatest within the first 3 days after onset of symptoms and diminishes rapidly as the course of infection proceeds (<link linkend="ch0101s0014s0003li0005">5</link>). In cases of disseminated disease or in immunocompromised patients, viruses may be identified in clinical samples for prolonged periods (<link linkend="ch0101s0014s0003li0006">6</link>). Generally, the level and duration of virus shedding depend on the virus, infected organ or organ system, and host factors such as age and immune status (<link linkend="ch0101s0014s0003li0007">7</link>–<link linkend="ch0101s0014s0003li0009">9</link>). Specimens with high concentrations of viral particles, viral antigens (Ags), or viral nucleic acids (NAs) will improve the laboratory’s ability to make an accurate diagnosis. Specimen collection techniques can greatly affect specimen quality and, therefore, test results. Collecting an adequate specimen is straightforward when fluids (e.g., CSF, blood, and urine) are sampled, as standard collection procedures are used and are not subject to great variability. However, collection of swab specimens is prone to variability, which can affect the amount of infectious virus, viral nucleic acids, or viral antigens present on the swab.</para>
        <anchor id="ch0101s0001s0002a0003"/>
        <beginpage pagenum="1620"/>
        <anchor id="ch0101s0001s0002a0004"/>
        <beginpage pagenum="1621"/>
        <anchor id="ch0101s0001s0002a0005"/>
        <beginpage pagenum="1622"/>
        <table id="ch0101s0001s0002t0001"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0101s0001s0002a0006"/><link linkend="ch0101s0001a0003">TABLE 1</link></phrase></emphasis> Specimens and methods for detection of viruses
</title>
          
          <tgroup cols="4">
            <tbody>
              <row>
                <entry><phrase role="center">Source and syndrome</phrase>
                </entry>
                <entry><phrase role="center">Virus(es)<superscript><link linkend="ch0101s0001s0002a0013"><emphasis>a</emphasis></link></superscript></phrase>
                  <anchor id="ch0101s0001s0002a0007"/>
                </entry>
                <entry><phrase role="center">Specimen(s)<superscript><link linkend="ch0101s0001s0002a0014"><emphasis>b</emphasis></link></superscript></phrase>
                  <anchor id="ch0101s0001s0002a0008"/>
                </entry>
                <entry><phrase role="center">Test method(s)<superscript><link linkend="ch0101s0001s0002a0015"><emphasis>c</emphasis></link></superscript></phrase>
                  <anchor id="ch0101s0001s0002a0009"/>
                </entry>
              </row>
              <row>
                <entry>Cardiac</entry>
              </row>
              <row>
                <entry>Myocarditis/pericarditis</entry>
                <entry>Adenoviruses</entry>
                <entry>Blood, respiratory, tissue</entry>
                <entry>NAAT, histology, IA, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>CMV</entry>
                <entry>Blood, tissue, urine</entry>
                <entry>NAAT, histology, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Enteroviruses</entry>
                <entry>Blood, respiratory, stool, tissue</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Influenza viruses</entry>
                <entry>Respiratory, tissue</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry>Cutaneous</entry>
              </row>
              <row>
                <entry>Exanthematous rash</entry>
                <entry>Adenoviruses</entry>
                <entry>Blood, respiratory</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Chikungunya virus</entry>
                <entry>Blood, urine</entry>
                <entry>NAAT, serology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Dengue virus</entry>
                <entry>Blood, urine</entry>
                <entry>NAAT, IA, serology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>EBV</entry>
                <entry>Blood</entry>
                <entry>NAAT, serology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Enteroviruses</entry>
                <entry>Blood, respiratory, stool</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HHV-6</entry>
                <entry>Blood</entry>
                <entry>NAAT, serology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Measles virus</entry>
                <entry>Blood, respiratory, urine</entry>
                <entry>NAAT, serology, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Parvovirus B19</entry>
                <entry>Blood</entry>
                <entry>NAAT, serology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Rubella virus</entry>
                <entry>Blood, respiratory, urine</entry>
                <entry>NAAT, serology, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Zika virus</entry>
                <entry>Blood, urine</entry>
                <entry>NAAT, serology</entry>
              </row>
              <row>
                <entry>Papillomas/papules</entry>
                <entry>Molluscum contagiosum</entry>
                <entry>Tissue</entry>
                <entry>Cytology, histology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Human papillomaviruses</entry>
                <entry>Tissue/cells</entry>
                <entry>Cytology, histology, NAAT</entry>
              </row>
              <row>
                <entry>Vesicular rash</entry>
                <entry>Enteroviruses</entry>
                <entry>Blood, respiratory, stool, vesicle</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HSV</entry>
                <entry>Lesion</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Poxviruses<superscript><link linkend="ch0101s0001s0002a0016"><emphasis>d</emphasis></link></superscript><anchor id="ch0101s0001s0002a0010"/></entry>
                <entry>lesion (vesicle, pustule, crust), oropharyngeal swab, anorectal swab, blood, tissue</entry>
                <entry>NAAT, histology, culture, EM</entry>
              </row>
              <row>
                <entry></entry>
                <entry>VZV</entry>
                <entry>Respiratory, vesicle</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry>Gastrointestinal</entry>
              </row>
              <row>
                <entry>Diarrhea</entry>
                <entry>Adenoviruses 40 and 41</entry>
                <entry>Stool</entry>
                <entry>NAAT, IA</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Astroviruses</entry>
                <entry>Stool</entry>
                <entry>NAAT</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Caliciviruses</entry>
                <entry>Stool</entry>
                <entry>NAAT</entry>
              </row>
              <row>
                <entry></entry>
                <entry>CMV</entry>
                <entry>Blood, stool, tissue</entry>
                <entry>NAAT, histology, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Human bocavirus</entry>
                <entry>Stool</entry>
                <entry>NAAT</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Parechoviruses</entry>
                <entry>Stool</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Rotavirus</entry>
                <entry>Stool</entry>
                <entry>NAAT, IA</entry>
              </row>
              <row>
                <entry>Hepatitis</entry>
                <entry>Adenoviruses</entry>
                <entry>Blood, tissue</entry>
                <entry>NAAT, histology, IA, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>CMV</entry>
                <entry>Blood, tissue</entry>
                <entry>NAAT, histology, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>EBV</entry>
                <entry>Blood</entry>
                <entry>NAAT, serology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HAV</entry>
                <entry>Blood</entry>
                <entry>Serology, NAAT</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HBV</entry>
                <entry>Blood</entry>
                <entry>Serology, IA, NAAT</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HCV</entry>
                <entry>Blood</entry>
                <entry>Serology, NAAT</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HDV</entry>
                <entry>Blood</entry>
                <entry>Serology, IA, NAAT</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HEV</entry>
                <entry>Blood</entry>
                <entry>NAAT, serology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HSV</entry>
                <entry>Blood, tissue</entry>
                <entry>NAAT, histology, IA, culture</entry>
              </row>
              <row>
                <entry>Hematologic</entry>
              </row>
              <row>
                <entry>Bone marrow suppression</entry>
                <entry>CMV</entry>
                <entry>Blood, bone marrow</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Dengue virus</entry>
                <entry>Blood, bone marrow</entry>
                <entry>NAAT, serology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>EBV</entry>
                <entry>Blood, bone marrow</entry>
                <entry>NAAT, histology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HAV</entry>
                <entry>Blood</entry>
                <entry>NAAT, serology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HBV</entry>
                <entry>Blood</entry>
                <entry>NAAT, serology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HCV</entry>
                <entry>Blood</entry>
                <entry>NAAT, serology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HHV-6</entry>
                <entry>Blood, bone marrow</entry>
                <entry>NAAT</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HHV-8</entry>
                <entry>Blood, bone marrow</entry>
                <entry>NAAT, histology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HIV-1</entry>
                <entry>Blood</entry>
                <entry>NAAT, serology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Parvovirus B19</entry>
                <entry>Blood, bone marrow</entry>
                <entry>NAAT, serology</entry>
              </row>
              <row>
                <entry>Hemolytic anemia</entry>
                <entry>CMV</entry>
                <entry>Blood, bone marrow</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>EBV</entry>
                <entry>Blood, bone marrow</entry>
                <entry>NAAT, histology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HBV</entry>
                <entry>Blood</entry>
                <entry>NAAT, serology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HCV</entry>
                <entry>Blood</entry>
                <entry>NAAT, serology</entry>
              </row>
              <row>
                <entry>Lymphoid (B- and T-cell) disorders</entry>
                <entry><para id="ch0101s0001s0002p0002">EBV</para>
                  <para id="ch0101s0001s0002p0003">CMV</para>
                </entry>
                <entry><para id="ch0101s0001s0002p0004">Blood, bone marrow</para>
                  <para id="ch0101s0001s0002p0005">Blood, bone marrow</para>
                </entry>
                <entry><para id="ch0101s0001s0002p0006">NAAT, histology</para>
                  <para id="ch0101s0001s0002p0007">NAAT, IA, culture</para>
                </entry>
              </row>
              <row>
                <entry></entry>
                <entry>HIV-1</entry>
                <entry>Blood</entry>
                <entry>NAAT, serology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HHV-8</entry>
                <entry>Blood, bone marrow</entry>
                <entry>NAAT, IA</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HTLV-1</entry>
                <entry>Blood, bone marrow</entry>
                <entry>NAAT, serology</entry>
              </row>
              <row>
                <entry>Neonatal/fetal</entry>
                <entry>CMV</entry>
                <entry>Amniotic fluid, blood, saliva, urine</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Enteroviruses</entry>
                <entry>Blood, CSF, urine</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HBV</entry>
                <entry>Blood</entry>
                <entry>Serology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HIV</entry>
                <entry>Blood</entry>
                <entry>NAAT, serology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HSV</entry>
                <entry>Blood, CSF, vesicle</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Parechoviruses</entry>
                <entry>Blood, CSF, respiratory, urine</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Parvovirus B19</entry>
                <entry>Blood, amniotic fluid</entry>
                <entry>NAAT, serology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Rubella virus</entry>
                <entry>Blood, urine</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>VZV</entry>
                <entry>Amniotic fluid, blood, CSF, vesicle</entry>
                <entry>NAAT, IA serology, culture</entry>
              </row>
              <row>
                <entry>Neurologic</entry>
              </row>
              <row>
                <entry>Acute flaccid myelitis</entry>
                <entry>Arboviruses</entry>
                <entry>Blood, CSF</entry>
                <entry>NAAT, serology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Enteroviruses</entry>
                <entry>Blood, CSF, stool, respiratory</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry>Encephalitis</entry>
                <entry>Arboviruses</entry>
                <entry>Blood, CSF</entry>
                <entry>NAAT, serology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>BK virus</entry>
                <entry>CSF, tissue</entry>
                <entry>NAAT</entry>
              </row>
              <row>
                <entry></entry>
                <entry>CMV</entry>
                <entry>CSF</entry>
                <entry>NAAT</entry>
              </row>
              <row>
                <entry></entry>
                <entry>EBV</entry>
                <entry>CSF</entry>
                <entry>NAAT</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Enteroviruses</entry>
                <entry>CSF, respiratory, stool</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HHV-6</entry>
                <entry>CSF</entry>
                <entry>NAAT</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HSV</entry>
                <entry>CSF</entry>
                <entry>NAAT</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HIV</entry>
                <entry>CSF</entry>
                <entry>NAAT</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Measles virus</entry>
                <entry>Blood, CSF, urine</entry>
                <entry>NAAT, serology, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Mumps virus</entry>
                <entry>Blood, CSF, saliva, urine</entry>
                <entry>NAAT, serology, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Parechoviruses</entry>
                <entry>CSF</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Rabies</entry>
                <entry>Blood, CSF, saliva, tissue (nuchal)</entry>
                <entry>NAAT, IA, serology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>VZV</entry>
                <entry>CSF</entry>
                <entry>NAAT</entry>
              </row>
              <row>
                <entry>Meningitis</entry>
                <entry>Arboviruses</entry>
                <entry>Blood, CSF</entry>
                <entry>NAAT, serology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Enteroviruses</entry>
                <entry>CSF, respiratory, stool</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HSV</entry>
                <entry>CSF</entry>
                <entry>NAAT</entry>
              </row>
              <row>
                <entry></entry>
                <entry>LCMV</entry>
                <entry>Blood, CSF</entry>
                <entry>Serology, NAAT, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Mumps virus</entry>
                <entry>Blood, CSF, urine</entry>
                <entry>NAAT, serology, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Parechoviruses</entry>
                <entry>CSF</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>VZV</entry>
                <entry>CSF</entry>
                <entry>NAAT</entry>
              </row>
              <row>
                <entry>PML<superscript><link linkend="ch0101s0001s0002a0017"><emphasis>e</emphasis></link></superscript><anchor id="ch0101s0001s0002a0011"/></entry>
                <entry>JC virus</entry>
                <entry>CSF, tissue</entry>
                <entry>NAAT, histology</entry>
              </row>
              <row>
                <entry>Ocular</entry>
              </row>
              <row>
                <entry>Conjunctivitis</entry>
                <entry>Adenoviruses</entry>
                <entry>Eye swab, respiratory</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Enteroviruses</entry>
                <entry>Eye swab, respiratory</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HSV</entry>
                <entry>Eye swab</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry>Keratitis</entry>
                <entry>Adenoviruses</entry>
                <entry>Eye swab, respiratory</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Enteroviruses</entry>
                <entry>Eye swab, respiratory</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HSV</entry>
                <entry>Eye swab</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>VZV</entry>
                <entry>Eye swab</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry>Uveitis/retinitis</entry>
                <entry>CMV</entry>
                <entry>Intraocular fluid</entry>
                <entry>NAAT</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HSV</entry>
                <entry>Intraocular fluid</entry>
                <entry>NAAT</entry>
              </row>
              <row>
                <entry></entry>
                <entry>VZV</entry>
                <entry>Intraocular fluid</entry>
                <entry>NAAT</entry>
              </row>
              <row>
                <entry>Respiratory</entry>
              </row>
              <row>
                <entry>Bronchiolitis</entry>
                <entry>Adenoviruses</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Enteroviruses</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Human bocavirus</entry>
                <entry>Respiratory</entry>
                <entry>NAAT</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Human coronaviruses<superscript><link linkend="ch0101s0001s0002a0018"><emphasis>f</emphasis></link></superscript><anchor id="ch0101s0001s0002a0012"/></entry>
                <entry>Blood, respiratory</entry>
                <entry>NAAT, serology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Human metapneumovirus</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, IA</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Influenza viruses</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Parainfluenza viruses</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>RSV</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Rhinoviruses</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry>Croup</entry>
                <entry>Human bocavirus</entry>
                <entry>Respiratory</entry>
                <entry>NAAT</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Human coronaviruses<superscript><link linkend="ch0101s0001s0002a0018"><emphasis>f</emphasis></link></superscript></entry>
                <entry>Blood, respiratory</entry>
                <entry>NAAT, serology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Human metapneumovirus</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, IA</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Influenza viruses</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Parainfluenza viruses</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Rhinoviruses</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>RSV</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry>Parotitis</entry>
                <entry>Adenoviruses</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>CMV</entry>
                <entry>Blood, respiratory</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>EBV</entry>
                <entry>Blood</entry>
                <entry>NAAT, serology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Enteroviruses</entry>
                <entry>Blood, respiratory, stool</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HIV-1</entry>
                <entry>Blood</entry>
                <entry>Serology, NAAT</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Mumps virus</entry>
                <entry>Blood, respiratory, urine</entry>
                <entry>NAAT, serology, culture</entry>
              </row>
              <row>
                <entry>Pharyngitis/URI</entry>
                <entry>Adenoviruses</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>EBV</entry>
                <entry>Blood</entry>
                <entry>Serology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Enteroviruses</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HSV</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Human coronaviruses<superscript><link linkend="ch0101s0001s0002a0018"><emphasis>f</emphasis></link></superscript></entry>
                <entry>Respiratory</entry>
                <entry>NAAT, IA</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Human metapneumovirus</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, IA</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Influenza viruses</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Parainfluenza viruses</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Rhinoviruses</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>RSV</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry>Pleurodynia</entry>
                <entry>Enteroviruses</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry>Pneumonia</entry>
                <entry>Adenoviruses</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>CMV</entry>
                <entry>Blood, respiratory, tissue</entry>
                <entry>NAAT, IA, histology, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Hantaviruses</entry>
                <entry>Blood, tissue</entry>
                <entry>NAAT, serology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HSV</entry>
                <entry>Respiratory, tissue</entry>
                <entry>NAAT, histology, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Human coronaviruses<superscript><link linkend="ch0101s0001s0002a0018"><emphasis>f</emphasis></link></superscript></entry>
                <entry>Blood, respiratory</entry>
                <entry>NAAT, serology</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Human metapneumovirus</entry>
                <entry>Respiratory</entry>
                <entry>NAAT</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Influenza viruses</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Measles virus</entry>
                <entry>Blood, respiratory, urine</entry>
                <entry>NAAT, serology, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Parainfluenza viruses</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Rhinoviruses</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>RSV</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>VZV</entry>
                <entry>Respiratory, tissue</entry>
                <entry>NAAT, histology, culture</entry>
              </row>
              <row>
                <entry>Rhinitis/coryza</entry>
                <entry>Adenoviruses</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Enteroviruses</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Human coronaviruses<superscript><link linkend="ch0101s0001s0002a0018"><emphasis>f</emphasis></link></superscript></entry>
                <entry>Respiratory</entry>
                <entry>NAAT</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Human metapneumovirus</entry>
                <entry>Respiratory</entry>
                <entry>NAAT</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Influenza viruses</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Parainfluenza viruses</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>Rhinoviruses</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>RSV</entry>
                <entry>Respiratory</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry>Urogenital</entry>
              </row>
              <row>
                <entry>Cervicitis/urethritis</entry>
                <entry>Adenoviruses</entry>
                <entry>Genital</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>CMV</entry>
                <entry>Genital, tissue</entry>
                <entry>NAAT, histology, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>HSV</entry>
                <entry>Genital</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry>Genital warts, carcinoma</entry>
                <entry>HPV</entry>
                <entry>Genital, tissue</entry>
                <entry>NAAT, histology</entry>
              </row>
              <row>
                <entry>Hemorrhagic cystitis</entry>
                <entry>Adenoviruses</entry>
                <entry>Urine</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>BK virus</entry>
                <entry>Urine</entry>
                <entry>NAAT</entry>
              </row>
              <row>
                <entry></entry>
                <entry>CMV</entry>
                <entry>Urine</entry>
                <entry>NAAT, culture</entry>
              </row>
              <row>
                <entry>Herpetic lesions</entry>
                <entry>HSV</entry>
                <entry>Lesion</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry></entry>
                <entry>VZV</entry>
                <entry>Lesion</entry>
                <entry>NAAT, IA, culture</entry>
              </row>
              <row>
                <entry>Orchitis/epididymitis</entry>
                <entry>Mumps virus</entry>
                <entry>Blood</entry>
                <entry>Serology</entry>
              </row>
              <row>
                <entry>Papules</entry>
                <entry>Molluscum contagiosum virus</entry>
                <entry>Tissue</entry>
                <entry>Histology</entry>
              </row>
              <row>
                <entry>Proctitis</entry>
                <entry>HSV</entry>
                <entry>Rectal</entry>
                <entry>NAAT, culture</entry>
              </row>
            </tbody>
          </tgroup>
        </table>
        <para id="ch0101s0001s0002p0008" role="table-footnote"><superscript><link linkend="ch0101s0001s0002a0007"><emphasis>a</emphasis></link></superscript><anchor id="ch0101s0001s0002a0013"/>Refer to specific chapters in this <emphasis>Manual</emphasis> for individual viruses; only common viral pathogens are listed. HHV-6, human herpes virus 6; HAV, hepatitis A virus; HTLV-1, human T-cell lymphotropic virus 1; LCMV, lymphocytic choriomeningitis virus.</para>
        <para id="ch0101s0001s0002p0009" role="table-footnote"><superscript><link linkend="ch0101s0001s0002a0008"><emphasis>b</emphasis></link></superscript><anchor id="ch0101s0001s0002a0014"/>Common specimens for viral diagnostics; refer to specific chapters for individual viruses. Respiratory includes throat and nasal swabs, nasal wash, NP aspirate, tracheal, and BAL specimens. Eye specimens include swabs of conjunctiva or cornea in VTM, and intraocular aqueous and vitreous fluids.</para>
        <para id="ch0101s0001s0002p0010" role="table-footnote"><superscript><link linkend="ch0101s0001s0002a0009"><emphasis>c</emphasis></link></superscript><anchor id="ch0101s0001s0002a0015"/>Common detection methods used include EM, electron microscopy; IA, antigen immunoassay (such as immunofluorescence-antibody assay, enzyme-linked immunosorbent assay, or immunochromatographic test); NAAT, nucleic acid amplification test.</para>
        <para id="ch0101s0001s0002p0011" role="table-footnote"><superscript><link linkend="ch0101s0001s0002a0010"><emphasis>d</emphasis></link></superscript><anchor id="ch0101s0001s0002a0016"/>Smallpox virus as well as hemorrhagic fever viruses (e.g., Ebola virus and Marburg virus) require processing in BSL-4 facilities. MPOX virus culture requires BSL-3 facilities.</para>
        <para id="ch0101s0001s0002p0012" role="table-footnote"><superscript><link linkend="ch0101s0001s0002a0011"><emphasis>e</emphasis></link></superscript><anchor id="ch0101s0001s0002a0017"/>PML, progressive multifocal leukoencephalopathy.</para>
        <para id="ch0101s0001s0002p0013" role="table-footnote"><superscript><link linkend="ch0101s0001s0002a0012"><emphasis>f</emphasis></link></superscript><anchor id="ch0101s0001s0002a0018"/>Human coronaviruses including SARS-CoV-2.</para>
        <para id="ch0101s0001s0002p0014">For serologic diagnosis, the timing of serum collection and type of antibody detected vary for specific viruses. An acute-phase serum specimen should be obtained early in the course of illness for virus-specific IgM testing. Convalescent-phase serum for IgG testing should be obtained 2 to 4 weeks after the acute-phase specimen or symptom resolution, and ideally both acute and convalescent specimens should be tested concurrently to identify any significant changes in antibody concentration. However, due to the delay in collecting a convalescent-phase specimen, the final result will generally not impact patient treatment, and for this reason, convalescent-phase serologic testing is infrequently performed. For some viruses (e.g., severe acute respiratory syndrome coronavirus-1 [SARS-CoV-1]), timing of the collection of the convalescent-phase specimen may extend beyond 4 weeks after the onset of symptoms to reliably rule out infection (<link linkend="ch0101s0014s0003li0010">10</link>). Additionally, in disease due to reactivation of latent or persistent viruses, there may or may not be a detectable rise in IgM and/or IgG levels. Generally, IgM is more sensitive to freezing and thawing than is IgG, so repeated freeze/thaw cycles should be avoided.</para>
        <anchor id="ch0101s0001s0002a0019"/>
        <beginpage pagenum="1623"/>
        <para id="ch0101s0001s0002p0015">Health care workers who collect specimens from patients should wear personal protective equipment as appropriate for standard, contact, airborne, or droplet precautions (<link linkend="ch0101s0014s0003li0011">11</link>, <link linkend="ch0101s0014s0003li0012">12</link>). The laboratory should always be notified in advance if rare agents representing a danger to laboratory workers (e.g., hemorrhagic fever viruses and novel respiratory viruses) are suspected. Samples in which such viruses are suspected should not be manipulated in laboratories that lack the ability to undertake such handling under the appropriate biosafety level conditions. Some specimens can be handled under enhanced biosafety level 2 (BSL-2) or BSL-3 conditions for certain viruses. Likewise, laboratories should provide instructions to those collecting and submitting specimens from individuals suspected of harboring a BSL-3 or BSL-4 pathogen. These should not be cultured in routine BSL-2 clinical laboratories, but rather referred to the relevant state public health laboratory or the Centers for Disease Control and Prevention (CDC; Atlanta, GA). Manipulation of these specimens and tissues, including sera obtained from convalescent patients, may pose a serious biohazard and should be minimized outside a BSL-4 laboratory. Use of vacuum tube collection systems is considered safer than use of syringes and needles, which must be disassembled before their contents are transferred to another tube. Procedures that generate aerosols should be minimized. NA extraction procedures, conducted in a biosafety cabinet (BSC), have the advantage of inactivating viruses prior to analysis (<link linkend="ch0101s0014s0003li0013">13</link>). The appropriate CDC guideline should be consulted for specific information regarding the handling of specimens suspected to contain high-risk pathogens.</para>
      </sect2>
      <sect2 id="ch0101s0001s0003">
        <title>TRANSPORT MEDIUM</title>
        <anchor id="ch0101s0001s0003a0001"/>
        <anchor id="ch0101s0001s0003a0002"/>
        <para id="ch0101s0001s0003p0001">Depending on the specimen source and type of testing requested, it may be appropriate to place the sample in viral transport medium (VTM). Liquid specimens, such as amniotic fluid, blood, CSF, urine, and bronchoalveolar lavage (BAL) fluid, do not generally require VTM (<link linkend="ch0101s0014s0003li0014">14</link>). Specimens that are susceptible to drying (e.g., swabs and tissue) must be kept moist in VTM or other buffered solutions designed to maintain the titer of infectious virions for culture, the stability of viral antigens for direct antigen tests, or viral NAs for nucleic acid amplification tests (NAATs). However, molecular testing can be an exception, as certain NAs have been found to be quite stable in a desiccated state. Dried samples for NAAT have the advantage of (i) relatively long storage capability at room temperature, (ii) reduced biohazard risk to laboratory personnel, with no spill risk and reduced infectivity, and (iii) simple and inexpensive ambient-temperature shipping of specimens where maintenance of a cold chain is limited. However, the versatility of a liquid specimen offers obvious advantages (i.e., it can be split and tested by multiple methods). When a complete microbiological workup on a specimen is requested, including viral, bacterial, mycobacterial, and fungal testing, VTM should not be added to the specimen, as this medium contains both antibacterial and antifungal agents. Rather, samples should be collected independently or aliquoted into the appropriate transport media.</para>
        <para id="ch0101s0001s0003p0002">The most useful types of transport systems should allow simultaneous detection of viruses by any number of methods, including culture, Ag detection, and NAAT. Although some common viral agents can withstand extended storage in suitable transport media at room temperature, it is generally the case that virus replication competency decreases over time, and at higher temperatures, this rate of decay is often accelerated. To stabilize the rate of decay, viral transport systems are usually kept on ice until they can be processed for testing. The optimal transport medium should further stabilize virus replication competency with minimal loss of virus titer, contain components to control potential microbial contamination, have a long shelf life, and be readily available at a reasonable cost (<link linkend="ch0101s0014s0003li0014">14</link>, <link linkend="ch0101s0014s0003li0015">15</link>). Formulations of VTM typically consist of a buffered salt solution, such as Hanks balanced salt solution buffered with HEPES to maintain a neutral pH, protein-stabilizing agents such as bovine serum albumin or gelatin, and antimicrobials to prevent bacterial and/or fungal overgrowth. Some laboratories have reported that media designed for collection and transport of bacteriology specimens are also acceptable for collection and transport of viral specimens. Under experimental conditions, bacteriologic swab transport systems allowed NA detection of influenza A virus, echovirus 30, herpes simplex virus 2 (HSV-2), and adenovirus up to 5 days after storage at 4°C or room temperature, albeit with lower sensitivity than swabs in VTM (<link linkend="ch0101s0014s0003li0016">16</link>).</para>
        <para id="ch0101s0001s0003p0003">VTM can be prepared in the laboratory or purchased (<anchor id="ch0101s0001s0003a0003"/><link linkend="ch0101s0001s0003a0004">Table 2</link>). An advantage of commercially prepared media is that the burden of quality control is shifted from the laboratory to the manufacturer (<link linkend="ch0101s0014s0003li0017">17</link>). Some transport media also sustain the viability of chlamydiae, mycoplasmas, and ureaplasmas, though culture of these organisms for clinical diagnoses is not commonly performed. The inclusion of sucrose in the medium serves as a cryoprotectant to maintain the integrity of viruses if specimens are frozen (≤–70°C) for prolonged periods. Laboratories should validate the suitability of their selected media for their particular applications, as performances can vary (<link linkend="ch0101s0014s0003li0017">17</link>, <link linkend="ch0101s0014s0003li0018">18</link>).</para>
        <para id="ch0101s0001s0003p0004">Manufacturers of commercial assays for NAAT or Ag detection either supply transport media or make recommendations for transport systems that are compatible with their test methods. The manufacturer’s package insert should therefore be consulted for information on appropriate collection and transport systems. Most VTM are compatible with NA and Ag detection tests (<link linkend="ch0101s0014s0003li0014">14</link>, <link linkend="ch0101s0014s0003li0019">19</link>). However, note that deviation from the transport media recommended by the manufacturer in the FDA <emphasis>in vitro</emphasis> diagnostic package insert requires an in-house validation.</para>
        <table id="ch0101s0001s0003t0001"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0101s0001s0003a0004"/><link linkend="ch0101s0001s0003a0003">TABLE 2</link></phrase></emphasis> Selected commercial sources of transport media for viral diagnostics
</title>
          
          <tgroup cols="4">
            <tbody>
              <row>
                <entry><phrase role="center">Medium</phrase>
                </entry>
                <entry><phrase role="center">Composition</phrase>
                </entry>
                <entry><phrase role="center">Vol (ml)</phrase>
                </entry>
                <entry><phrase role="center">Storage temp (°C)</phrase>
                </entry>
              </row>
              <row>
                <entry>BD Universal VTM<superscript><link linkend="ch0101s0001s0003a0008">a</link>,<link linkend="ch0101s0001s0003a0010"><emphasis>c</emphasis></link></superscript><anchor id="ch0101s0001s0003a0005"/><anchor id="ch0101s0001s0003a0006"/> (BD Diagnostics)</entry>
                <entry>Basal constituents<superscript><link linkend="ch0101s0001s0003a0009"><emphasis>b</emphasis></link></superscript><anchor id="ch0101s0001s0003a0007"/>, gelatin, <phrase role="small">L</phrase>-cysteine, sucrose, colistin, vancomycin</entry>
                <entry><phrase role="center">1, 3</phrase>
                </entry>
                <entry><phrase role="center">2–25</phrase>
                </entry>
              </row>
              <row>
                <entry>Copan Universal transport medium<superscript><link linkend="ch0101s0001s0003a0010"><emphasis>c</emphasis></link></superscript> (Copan Diagnostics)</entry>
                <entry>Basal constituents, gelatin,<phrase role="small">L</phrase>-cysteine, sucrose, colistin, vancomycin</entry>
                <entry><phrase role="center">3, 6</phrase>
                </entry>
                <entry><phrase role="center">2–25</phrase>
                </entry>
              </row>
              <row>
                <entry>Hardy VTM<superscript><link linkend="ch0101s0001s0003a0010"><emphasis>c</emphasis></link></superscript> (Hardy Diagnostics)</entry>
                <entry>Basal constituents, gentamicin</entry>
                <entry><phrase role="center">3</phrase>
                </entry>
                <entry><phrase role="center">2–30</phrase>
                </entry>
              </row>
              <row>
                <entry>FlexTrans VTM (Trinity Biotech)</entry>
                <entry>Basal constituents, sucrose, gentamicin, streptomycin</entry>
                <entry><phrase role="center">3</phrase>
                </entry>
                <entry><phrase role="center">2–8</phrase>
                </entry>
              </row>
              <row>
                <entry>Meridian viral transport<superscript><link linkend="ch0101s0001s0003a0010"><emphasis>c</emphasis></link></superscript> (Meridian Bioscience)</entry>
                <entry>Tryptose phosphate broth, gelatin, gentamicin</entry>
                <entry><phrase role="center">1.5</phrase>
                </entry>
                <entry><phrase role="center">2–25</phrase>
                </entry>
              </row>
              <row>
                <entry>MicroTest M4<superscript><link linkend="ch0101s0001s0003a0010"><emphasis>c</emphasis></link></superscript> (Remel)</entry>
                <entry>Basal constituents, gelatin, sucrose, colistin, vancomycin</entry>
                <entry><phrase role="center">3</phrase>
                </entry>
                <entry><phrase role="center">2–8</phrase>
                </entry>
              </row>
              <row>
                <entry>MicroTest M4RT<superscript><link linkend="ch0101s0001s0003a0010"><emphasis>c</emphasis></link></superscript> (Remel)</entry>
                <entry>Basal constituents, gelatin, sucrose, gentamicin</entry>
                <entry><phrase role="center">3</phrase>
                </entry>
                <entry><phrase role="center">2–30</phrase>
                </entry>
              </row>
              <row>
                <entry>MicroTest M5<superscript><link linkend="ch0101s0001s0003a0010"><emphasis>c</emphasis></link></superscript> (Remel)</entry>
                <entry>Basal constituents, protein stabilizers, sucrose, colistin, vancomycin</entry>
                <entry><phrase role="center">3</phrase>
                </entry>
                <entry><phrase role="center">2–8</phrase>
                </entry>
              </row>
              <row>
                <entry>MicroTest M6<superscript><link linkend="ch0101s0001s0003a0010"><emphasis>c</emphasis></link></superscript> (Remel)</entry>
                <entry>Basal constituents, gelatin, sucrose, colistin, vancomycin</entry>
                <entry><phrase role="center">1.5</phrase>
                </entry>
                <entry><phrase role="center">2–30</phrase>
                </entry>
              </row>
              <row>
                <entry>Multitrans medium<superscript><link linkend="ch0101s0001s0003a0010"><emphasis>c</emphasis></link></superscript> (Starplex Scientific)</entry>
                <entry>Basal constituents, gelatin, sucrose, sodium bicarbonate, colistin, vancomycin</entry>
                <entry><phrase role="center">3</phrase>
                </entry>
                <entry><phrase role="center">4–25</phrase>
                </entry>
              </row>
              <row>
                <entry>Puritan UniTranz-RT<superscript><link linkend="ch0101s0001s0003a0010"><emphasis>c</emphasis></link></superscript> (Puritan Medical)</entry>
                <entry>Basal constituents, gelatin, sucrose, colistin, vancomycin</entry>
                <entry><phrase role="center">1, 3</phrase>
                </entry>
                <entry><phrase role="center">2–25</phrase>
                </entry>
              </row>
              <row>
                <entry>Sigma-VCM medium<superscript><link linkend="ch0101s0001s0003a0010"><emphasis>c</emphasis></link></superscript> (Medical Wire &amp; Equipment)</entry>
                <entry>Balanced salt solution, HEPES, disodium hydrogen orthophosphate, sucrose, lactalbumin hydrolysate, colistin, vancomycin</entry>
                <entry><phrase role="center">1, 1.5, 3</phrase>
                </entry>
                <entry><phrase role="center">5–25</phrase>
                </entry>
              </row>
              <row>
                <entry>Sigma-Virocult medium<superscript><link linkend="ch0101s0001s0003a0010"><emphasis>c</emphasis></link></superscript> (Medical Wire &amp; Equipment)</entry>
                <entry>Balanced salt solution, disodium hydrogen orthophosphate, lactalbumin hydrolysate, chloramphenicol</entry>
                <entry><phrase role="center">1, 2, 3</phrase>
                </entry>
                <entry><phrase role="center">5–25</phrase>
                </entry>
              </row>
              <row>
                <entry>ViraTrans medium (Trinity Biotech)</entry>
                <entry>Basal constituents, gentamicin, penicillin, streptomycin</entry>
                <entry><phrase role="center">2</phrase>
                </entry>
                <entry><phrase role="center">2–8</phrase>
                </entry>
              </row>
              <row>
                <entry>HealthLink Universal transport media<superscript><link linkend="ch0101s0001s0003a0010"><emphasis>c</emphasis></link></superscript> (Diagnostic Hybrids)</entry>
                <entry>Basal constituents, gelatin, sucrose,<phrase role="small">L</phrase>-cysteine, colistin, vancomycin</entry>
                <entry><phrase role="center">1, 3</phrase>
                </entry>
                <entry><phrase role="center">2–25</phrase>
                </entry>
              </row>
            </tbody>
          </tgroup>
        </table>
        <para id="ch0101s0001s0003p0005" role="table-footnote"><superscript><link linkend="ch0101s0001s0003a0005"><emphasis>a</emphasis></link></superscript><anchor id="ch0101s0001s0003a0008"/>VTM, viral transport medium.</para>
        <para id="ch0101s0001s0003p0006" role="table-footnote"><superscript><link linkend="ch0101s0001s0003a0007"><emphasis>b</emphasis></link></superscript><anchor id="ch0101s0001s0003a0009"/>Basal constituents: Hanks balanced salt solution, bovine serum albumin, <phrase role="small">L</phrase>-glutamic acid, HEPES buffer (pH 7.3), phenol red, amphotericin B.</para>
        <para id="ch0101s0001s0003p0007" role="table-footnote"><superscript><link linkend="ch0101s0001s0003a0006"><emphasis>c</emphasis></link></superscript><anchor id="ch0101s0001s0003a0010"/>Product available as swab-transport tube combination.</para>
      </sect2>
      <sect2 id="ch0101s0001s0004">
        <title>TRANSPORT CONDITIONS</title>
        <anchor id="ch0101s0001s0004a0001"/>
        <anchor id="ch0101s0001s0004a0002"/>
        <para id="ch0101s0001s0004p0001">Once a clinical specimen has been collected, it should be transported to the laboratory as soon as possible, since virus replication competency decreases with time (i.e., some clinically important viruses are more labile than others). The optimal time and temperature for transport, processing, and storage (discussed below) of specimens should be adhered to in order to generate accurate and meaningful results. Typically, specimens for viral culture should be transported to the laboratory promptly (ideally, within 2 to 4 h of collection), since overall diagnostic yield improves when specimens are expeditiously processed for viral culture. The preferred transport temperature for specimens for viral culture is 2 to 8°C. Enzymes present in specimens and capable of inactivating viruses or degrading proteins and nucleic acids are less active at refrigeration temperatures. For longer transport times or submission to reference laboratories, specimens should be stored and shipped under conditions that preserve the integrity of the sample. For example, it may be necessary to transport serum or plasma collected for NA testing frozen. Viability is not a requirement for Ag or NA detection methods; therefore, transport time may be less significant, unless degradation of intact cells, viral proteins, or viral NA is a consideration. However, for timely diagnosis, delay should be avoided during transport of these specimens to the laboratory.</para>
        <anchor id="ch0101s0001s0004a0003"/>
        <beginpage pagenum="1624"/>
      </sect2>
      <sect2 id="ch0101s0001s0005">
        <title>SPECIMEN STORAGE AND PROCESSING</title>
        <anchor id="ch0101s0001s0005a0001"/>
        <anchor id="ch0101s0001s0005a0002"/>
        <para id="ch0101s0001s0005p0001">Accredited laboratories are required to specify rejection criteria for specimens that are collected, transported, or stored under improper conditions. Specimens that are unacceptable for testing include those that are (i) unlabeled or improperly labeled, (ii) received in improper or leaking containers, (iii) not appropriate or validated for a particular test, (iv) transported under improper conditions, or (v) received beyond the acceptable transport time limit. At a minimum, the specimen container should be labeled with the patient’s full name, a medical record number or unique identifier, the date and time of collection, the specific source, and the name of the collector. Each specimen should be accompanied by a requisition (hard copy or electronic) containing the same information as the specimen container, as well as the patient’s location, test(s) requested, source of the specimen, requesting clinician with contact information, and suspected clinical diagnosis (<link linkend="ch0101s0014s0003li0020">20</link>). Specimens deemed unacceptable that cannot be re-collected (e.g., tissue collected during surgery) may be processed and tested according to the laboratory’s clearly defined procedure allowing such exceptions.</para>
        <para id="ch0101s0001s0005p0002">Specimens submitted for virus culture can be held at refrigerated temperature (2 to 8°C) for up to 2 days prior to inoculation onto cell culture. Many viruses lose infectivity at ambient or even refrigeration temperatures. For example, 90% of respiratory syncytial virus (RSV) infectivity is lost after 4 days at 4°C and 24 h at 37°C (<link linkend="ch0101s0014s0003li0021">21</link>). Freezing of specimens (≤–70°C) is not recommended for virus culture, unless specimen processing will not occur within 2 days. The temperature in standard freezers (–20°C) is not low enough to maintain virus infectivity. Certain viruses may also lose infectivity with repeated freeze-thaw cycles, particularly enveloped viruses. Detailed specimen processing protocols for viral culture have been described previously (<link linkend="ch0101s0014s0003li0022">22</link>, <link linkend="ch0101s0014s0003li0023">23</link>). Specimens should be processed using all appropriate biosafety guidelines (<link linkend="ch0101s0014s0003li0024">24</link>), and a biosafety cabinet should be used when manipulating specimens suspected to contain a virus(es) considered contagious by airborne routes.</para>
        <para id="ch0101s0001s0005p0003">Molecular assays are particularly sensitive to substandard preanalytical conditions. For RNA viruses such as HIV or HCV, the Clinical and Laboratory Standards Institute (CLSI) recommends that EDTA-treated whole-blood samples be centrifuged and the plasma be removed to a secondary tube within 4 h of phlebotomy, a conservative time frame that may vary depending on the assay manufacturer’s requirements (<link linkend="ch0101s0014s0003li0025">25</link>). However, studies have shown that for HIV-1 viral load testing, whole blood with EDTA and cell-free EDTA-treated plasma can be stored at room temperature for up to 30 h, at 4°C for up to 14 days, and at –70°C for extended periods of time without significant decreases in viral load signal (<link linkend="ch0101s0014s0003li0026">26</link>, <link linkend="ch0101s0014s0003li0027">27</link>), and HCV RNA is stable in EDTA-treated whole blood for at least 24 h at room temperature (<link linkend="ch0101s0014s0003li0028">28</link>). HIV proviral DNA can be detected in acid citrate dextrose (ACD)- or EDTA-treated whole blood for up to 10 days at both 4°C and ambient temperature (<link linkend="ch0101s0014s0003li0029">29</link>). The preanalytical steps for selected FDA-cleared/approved NAATs are listed in <anchor id="ch0101s0001s0005a0003"/><link linkend="ch0101s0001s0005a0005">Table 3</link>.</para>
        <anchor id="ch0101s0001s0005a0004"/>
        <beginpage pagenum="1625"/>
        <table id="ch0101s0001s0005t0001"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0101s0001s0005a0005"/><link linkend="ch0101s0001s0005a0003">TABLE 3</link></phrase></emphasis> Processing and storage conditions for blood specimens with selected FDA-cleared/approved NA tests
</title>
          
          <tgroup cols="5">
            <tbody>
              <row>
                <entry><phrase role="center">Test (manufacturer)</phrase>
                </entry>
                <entry><phrase role="center">Specimen types<superscript><link linkend="ch0101s0001s0005a0008"><emphasis>a</emphasis></link></superscript></phrase>
                  <anchor id="ch0101s0001s0005a0006"/>
                </entry>
                <entry><phrase role="center">Preparation conditions</phrase>
                </entry>
                <entry><phrase role="center">Short-term storage of plasma/serum</phrase>
                </entry>
                <entry><phrase role="center">Max. no. of freeze/thaw cycles</phrase>
                </entry>
              </row>
              <row>
                <entry>Alinity m HBV (Abbott)</entry>
                <entry>EDTA, ACD, PPT, or serum</entry>
                <entry>≤24 h, 15–30°C, or ≤72 h, 2–8°C</entry>
                <entry>≤20 h, 15–30°C; ≤3 days, 2–8°C; ≤60 days, –20°C; long term, –70°C</entry>
                <entry><phrase role="center">3<superscript><link linkend="ch0101s0001s0005a0009"><emphasis>b</emphasis></link></superscript></phrase>
                  <anchor id="ch0101s0001s0005a0007"/>
                </entry>
              </row>
              <row>
                <entry>Alinity m HCV (Abbott)</entry>
                <entry>EDTA, ACD, PPT, or serum</entry>
                <entry>≤24 h, 15–25°C, or ≤2 days, 2–8°C</entry>
                <entry>≤24 h, 15–25°C; ≤3 days, 2–8°C; ≤30 days, –20°C; long term, –70°C</entry>
                <entry><phrase role="center">2<superscript><link linkend="ch0101s0001s0005a0009"><emphasis>b</emphasis></link></superscript></phrase>
                </entry>
              </row>
              <row>
                <entry>Alinity m HIV (Abbott)</entry>
                <entry>EDTA, ACD, or PPT</entry>
                <entry>≤24 h, 15–30°C, or ≤2 days, 2–8°C</entry>
                <entry>≤24 h, 15–30°C; ≤3 days, 2–8°C; ≤60 days, –20°C; long term, –70°C</entry>
                <entry><phrase role="center">2<superscript><link linkend="ch0101s0001s0005a0009"><emphasis>b</emphasis></link></superscript></phrase>
                </entry>
              </row>
              <row>
                <entry>Aptima HBV Quant (Hologic)</entry>
                <entry>EDTA, ACD, PPT, or serum</entry>
                <entry>≤24 h, 2–30°C</entry>
                <entry>≤24 h, 2–30°C; ≤5 days, 2–8°C; ≤60 days, –20°C</entry>
                <entry><phrase role="center">3</phrase>
                </entry>
              </row>
              <row>
                <entry>Aptima HCV Quant Dx (Hologic)</entry>
                <entry>EDTA, ACD, PPT, or serum</entry>
                <entry>≤6 h, 2–30°C</entry>
                <entry>≤24 h, 2–25°C; ≤5 days, 2–8°C; ≤60 days, –20°C</entry>
                <entry><phrase role="center">3</phrase>
                </entry>
              </row>
              <row>
                <entry>Aptima HIV-1 Quant Dx (Hologic)</entry>
                <entry>EDTA, ACD, PPT, or serum</entry>
                <entry>≤24 h, 2–30°C</entry>
                <entry>≤5 days, 2–8°C; ≤90 days, –20 to –70°C</entry>
                <entry><phrase role="center">3</phrase>
                </entry>
              </row>
              <row>
                <entry>cobas AmpliPrep/cobas TaqMan CMV (Roche)</entry>
                <entry>EDTA</entry>
                <entry>≤24 h, –25°C</entry>
                <entry>≤7 days, 2–8°C; ≤6 wk, ≤–20°C</entry>
                <entry><phrase role="center">3</phrase>
                </entry>
              </row>
              <row>
                <entry>cobas AmpliPrep/cobas TaqMan HBV (Roche)</entry>
                <entry>EDTA or serum</entry>
                <entry>≤24 h, 2–25°C</entry>
                <entry>≤3 days, 25–30°C; ≤7 days, 2–8°C; ≤6 wk, –20 to –80°C</entry>
                <entry><phrase role="center">5</phrase>
                </entry>
              </row>
              <row>
                <entry>cobas AmpliPrep/cobas TaqMan HCV (Roche)</entry>
                <entry>EDTA, PPT, or serum</entry>
                <entry>≤24 h, 2–25°C</entry>
                <entry>≤3 days, 2–8°C; ≤6 wk, –20 to –80°C</entry>
                <entry><phrase role="center">5</phrase>
                </entry>
              </row>
              <row>
                <entry>cobas AmpliPrep/cobas TaqMan HIV-1 (Roche)</entry>
                <entry>EDTA</entry>
                <entry>≤24 h, 2–25°C</entry>
                <entry>≤24 h, 15–30°C; ≤6 days, 2–8°C; ≤6 wk, –20 to –80°C</entry>
                <entry><phrase role="center">5</phrase>
                </entry>
              </row>
              <row>
                <entry>cobas BKV (Roche)</entry>
                <entry>EDTA or PPT</entry>
                <entry>≤24 h, 2–25°C</entry>
                <entry>≤24 h, 2–30°C; ≤6 days, 2–8°C; ≤6 months, –15 to –80°C</entry>
                <entry><phrase role="center">4</phrase>
                </entry>
              </row>
              <row>
                <entry>cobas CMV (Roche)</entry>
                <entry>EDTA or PPT</entry>
                <entry>≤36 h, 2–25°C</entry>
                <entry>≤6 days, 2–8°C; 12 wk at ≤–18°C; ≤6 months, ≤–60°C</entry>
                <entry><phrase role="center">4</phrase>
                </entry>
              </row>
              <row>
                <entry>cobas EBV (Roche)</entry>
                <entry>EDTA or PPT</entry>
                <entry>≤24 h, 2–25°C</entry>
                <entry>≤24 h, 2–30°C; ≤6 days, 2–8°C; ≤6 months, –15 to –80°C</entry>
                <entry><phrase role="center">4</phrase>
                </entry>
              </row>
              <row>
                <entry>cobas HBV (Roche)</entry>
                <entry>EDTA or PPT</entry>
                <entry>≤24 h, 2–25°C</entry>
                <entry>≤6 days, 2–8°C; 12 wk at ≤–18°C; ≤6 months, ≤–60°C</entry>
                <entry><phrase role="center">4</phrase>
                </entry>
              </row>
              <row>
                <entry>cobas HCV (Roche)</entry>
                <entry>EDTA or PPT</entry>
                <entry>≤24 h, 2–25°C</entry>
                <entry>≤6 days, 2–8°C; 12 wk at ≤–18°C; ≤6 months, ≤–60°C</entry>
                <entry><phrase role="center">4</phrase>
                </entry>
              </row>
              <row>
                <entry>cobas HIV-1 (Roche)</entry>
                <entry>EDTA or PPT</entry>
                <entry>≤24 h, 2–25°C</entry>
                <entry>≤6 days, 2–8°C; 12 wk at ≤–18°C; ≤6 months, ≤–60°C</entry>
                <entry><phrase role="center">4</phrase>
                </entry>
              </row>
              <row>
                <entry>cobas HIV-1/HIV-2 Qualitative (Roche)</entry>
                <entry>EDTA, PPT, or serum</entry>
                <entry>≤24 h, 2–25°C</entry>
                <entry>≤24 h, 2–30°C; ≤5 days, 2–8°C; ≤6 wk, –20°C; long term, ≤–60°C</entry>
                <entry><phrase role="center">3</phrase>
                </entry>
              </row>
              <row>
                <entry>artus CMV RGQ MDx (Qiagen)</entry>
                <entry>EDTA</entry>
                <entry>≤24 h, 20–25°C</entry>
                <entry>≤24 h, 20–25°C; ≤8 wk, –15 to –30°C</entry>
                <entry><phrase role="center">2</phrase>
                </entry>
              </row>
              <row>
                <entry>RealTime HBV (Abbott)</entry>
                <entry>EDTA or serum</entry>
                <entry>≤6 h, 2–30°C</entry>
                <entry>≤24 h, 15–30°C; ≤3 days, 2–8°C; long term, ≤–20°C</entry>
                <entry><phrase role="center">1<superscript><link linkend="ch0101s0001s0005a0009"><emphasis>b</emphasis></link></superscript></phrase>
                </entry>
              </row>
              <row>
                <entry>RealTime HCV (Abbott)</entry>
                <entry>EDTA or serum</entry>
                <entry>≤6 h, 2–30°C</entry>
                <entry>≤24 h, 15–30°C; ≤3 days, 2–8°C; ≤60 days, ≤–70°C</entry>
                <entry><phrase role="center">1<superscript><link linkend="ch0101s0001s0005a0009"><emphasis>b</emphasis></link></superscript></phrase>
                </entry>
              </row>
              <row>
                <entry>RealTime HIV-1 (Abbott)</entry>
                <entry>EDTA or ACD</entry>
                <entry>≤6 h, 15–30°C, or ≤24 h, 2–8°C</entry>
                <entry>≤24 h, 15–30°C; ≤5 days, 2–8°C; ≤60 days, ≤–20°C</entry>
                <entry><phrase role="center">3<superscript><link linkend="ch0101s0001s0005a0009"><emphasis>b</emphasis></link></superscript></phrase>
                </entry>
              </row>
              <row>
                <entry>RealTime CMV (Abbott)</entry>
                <entry>EDTA</entry>
                <entry>≤24 h, 3–30°C</entry>
                <entry>≤24 h, 15–30°C; ≤5 days, 2–8°C; long term, ≤–70°C</entry>
                <entry><phrase role="center">3<superscript><link linkend="ch0101s0001s0005a0009"><emphasis>b</emphasis></link></superscript></phrase>
                </entry>
              </row>
            </tbody>
          </tgroup>
        </table>
        <para id="ch0101s0001s0005p0004" role="table-footnote"><superscript><link linkend="ch0101s0001s0005a0006"><emphasis>a</emphasis></link></superscript><anchor id="ch0101s0001s0005a0008"/>EDTA, ethylenediaminetetraacetic acid; ACD, acid citrate dextrose; PPT, plasma preparation tube.</para>
        <para id="ch0101s0001s0005p0005" role="table-footnote"><superscript><link linkend="ch0101s0001s0005a0007"><emphasis>b</emphasis></link></superscript><anchor id="ch0101s0001s0005a0009"/>Thaw specimens at 15 to 30°C or 2 to 8°C; once thawed, specimens may be stored at 2 to 8°C for ≤6 h.</para>
        <para id="ch0101s0001s0005p0006">When RNAlater (Qiagen, Germantown, MD), an RNA stabilization buffer, was used, HCV and HIV plasma viral loads were stable for up to 28 days at 37°C, and HCV viral loads were essentially equivalent after 5 days when samples were transported either frozen or in RNAlater at ambient temperature (<link linkend="ch0101s0014s0003li0030">30</link>). Under experimental conditions, nonenveloped and enveloped viruses, including HIV-1, retained infectivity after more than 72 h of storage at room temperature in RNAlater (<link linkend="ch0101s0014s0003li0031">31</link>). Arboviral RNA was stable for at least 35 days when virus-containing samples were stored at 4°C or –20°C in AVL buffer (Buffer A Viral Lysis, Qiagen), a lysis buffer for nucleic acid purification that contains guanidine isothiocyanate and RNase inhibitors (<link linkend="ch0101s0014s0003li0032">32</link>). AVL buffer has the added property of inactivating viral infectivity. Enterovirus RNA was shown to be stable in CSF specimens stored at 4°C and –80°C for up to 2 weeks, but the half-life in samples stored at room temperature was calculated to be 9 days. In nasopharyngeal (NP) wash specimens, there was a &gt;65% reduction in influenza A virus RNA concentration when samples were maintained at room temperature, 4°C, or –80°C for 2 weeks (<link linkend="ch0101s0014s0003li0033">33</link>). If no specific RNase inhibitors are used, long-term storage of diagnostic RNA samples should be done preferably at ≤–70°C to inhibit RNase activity, as RNase may limit the stability of RNA even in frozen samples at –20°C (<link linkend="ch0101s0014s0003li0034">34</link>).</para>
        <anchor id="ch0101s0001s0005a0010"/>
        <beginpage pagenum="1626"/>
        <para id="ch0101s0001s0005p0007">For DNA targets such as cytomegalovirus (CMV), the data on DNA quantification after storage are conflicting, with some studies reporting no decline in CMV DNA levels after 24 h (<link linkend="ch0101s0014s0003li0035">35</link>), 72 h (<link linkend="ch0101s0014s0003li0036">36</link>), and 2 weeks (<link linkend="ch0101s0014s0003li0037">37</link>), while another showed increased levels in blood stored at room temperature or at 4°C prior to plasma separation (<link linkend="ch0101s0014s0003li0038">38</link>). The increased levels of CMV DNA in plasma separated more than 2 h after collection may be falsely positive or elevated in latently infected patients due to the lysis of leukocytes and release of CMV into plasma during storage. In another study, CMV DNA in EDTA-treated blood was stable for 2 weeks when the samples were stored at room temperature, 4°C, and –80°C, whereas CMV DNA in serum had a half-life of &lt;1, 2, and 3 days when samples were stored at room temperature, 4°C, and –80°C, respectively (<link linkend="ch0101s0014s0003li0033">33</link>). There was no statistically significant decline in hepatitis B virus (HBV) DNA concentration in plasma stored at both 5°C and 25°C for up to 28 days (<link linkend="ch0101s0014s0003li0027">27</link>). For HSV, the quantity in oral and genital specimens stored in VTM for 16 months at –20°C was within 1 log of the original concentration for &gt;90% of specimens (<link linkend="ch0101s0014s0003li0039">39</link>). In CSF specimens, HSV DNA was detectable by PCR for up to 30 days when samples were stored at temperatures ranging from 23°C to –70°C (<link linkend="ch0101s0014s0003li0040">40</link>). Human papillomavirus (HPV) DNA stored in two commercial liquid-based cytology media at 2 to 8°C was stable for more than 2 years. However, the reproducibility of results after storage may be affected by the methods of nucleic acid extraction and detection (<link linkend="ch0101s0014s0003li0041">41</link>). Generally, DNA in tissue is stable for up to 24 h at 4°C, for at least 2 weeks at –20°C, and for at least 2 years at ≤–70°C (<link linkend="ch0101s0014s0003li0025">25</link>).</para>
        <para id="ch0101s0001s0005p0008">Fewer data are available regarding the stability of nucleic acids in stool specimens, although rotavirus RNA has been shown to be stable for up to 2.5 months at ambient temperature (<link linkend="ch0101s0014s0003li0042">42</link>). Adenovirus DNA in fresh stool collected on sodium dodecyl sulfate (SDS)–EDTA-treated chromatography paper strips was detected after 4 months of storage at –20 to 37°C (<link linkend="ch0101s0014s0003li0043">43</link>), and under experimental conditions, strips containing various concentrations of norovirus were stable for reverse transcription-PCR detection up to 2 months at temperatures ranging from –80 to 37°C (<link linkend="ch0101s0014s0003li0044">44</link>).</para>
      </sect2>
      <sect2 id="ch0101s0001s0006">
        <title>COLLECTION METHODS AND PROCESSING OF SELECTED SPECIMENS</title>
        <anchor id="ch0101s0001s0006a0001"/>
        <anchor id="ch0101s0001s0006a0002"/>
        <para id="ch0101s0001s0006p0001">For commercially available FDA-cleared/approved assays, laboratories must follow manufacturers’ instructions for collection and processing of specimens. Assay performance must be verified by the individual laboratory prior to implementing any change in the preanalytical steps described in the manufacturer’s package insert (<link linkend="ch0101s0014s0003li0045">45</link>, <link linkend="ch0101s0014s0003li0046">46</link>). For laboratory-developed tests (LDTs), each test site must establish and validate appropriate processing and storage conditions, the extent of which may rely on studies performed by the laboratory or those in published sources. Similarly, if the user changes any aspect of collection or processing for an FDA-cleared/approved assay, the laboratory is then required to perform the necessary validation experiments, as for an LDT.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0101s0002">
      <title>Amniotic Fluid</title>
      <anchor id="ch0101s0002a0001"/>
      <anchor id="ch0101s0002a0002"/>
      <para id="ch0101s0002p0001">Although rare, viral infections during pregnancy may be detrimental to the fetus or newborn. Testing amniotic fluid for viral pathogens is generally based on maternal history or ultrasound-guided indications. Fluid is collected by amniocentesis, and 2 to 5 ml should be submitted to the laboratory in a sterile container. NA detection methods are the most commonly used. NAs should be extracted from samples as soon as possible and stored at 2 to 8°C for up to 48 h or frozen at ≤–70°C if testing is delayed beyond 48 h (<link linkend="ch0101s0014s0003li0025">25</link>). Virus can be recovered in culture, but sensitivity is generally lower than that of NAAT.</para>
      <para id="ch0101s0002p0002">For the most accurate prenatal diagnosis of congenital CMV infection, amniotic fluid should be collected between 21 and 23 weeks of fetal gestation (<link linkend="ch0101s0014s0003li0047">47</link>, <link linkend="ch0101s0014s0003li0048">48</link>). If maternal varicella-zoster virus (VZV) infection occurs during the first or second trimester, VZV DNA may be detected in amniotic fluid, but its presence is not necessarily synonymous with the development of congenital varicella syndrome. The presence of parvovirus B19 in amniotic fluid should be correlated with other clinical and prenatal diagnostics, since up to 25% of asymptomatic fetuses may have detectable virus (<link linkend="ch0101s0014s0003li0048">48</link>).</para>
    </sect1>
    <sect1 id="ch0101s0003">
      <title>Blood</title>
      <anchor id="ch0101s0003a0001"/>
      <anchor id="ch0101s0003a0002"/>
      <para id="ch0101s0003p0001">Serum, plasma, purified peripheral blood leukocytes, and whole blood have all been used to detect and quantify viral pathogens. The most suitable blood compartment for testing depends on the virus targeted. Quantitative molecular methods performed on blood samples are useful in assessing patient prognosis, treatment response, and antiviral resistance. For viral load monitoring over time, it is particularly important that the sample matrix not be varied. Which blood compartment to test depends on the underlying condition of the patient and whether the viral target dictates that a cellular or cell-free portion be utilized (<link linkend="ch0101s0014s0003li0049">49</link>–<link linkend="ch0101s0014s0003li0052">52</link>).</para>
      <para id="ch0101s0003p0002">Approximately 3 to 5 ml of blood should be collected in the appropriate anticoagulant vacuum tube. For pediatric specimens, smaller volumes are acceptable, but less than 1 or 2 ml may be inadequate for testing. The most commonly used anticoagulants are EDTA, heparin, and ACD. Anticoagulated blood may be fractionated to allow recovery of leukocytes (see below). EDTA and ACD are the preferred anticoagulants for obtaining plasma for NA testing, since heparin is inhibitory to many NA amplification chemistries (<link linkend="ch0101s0014s0003li0025">25</link>). In addition, frozen EDTA-treated plasma specimens have improved NA stability compared to those treated with heparin (<link linkend="ch0101s0014s0003li0026">26</link>).</para>
      <para id="ch0101s0003p0003">Whole blood used for NA amplification must be processed to remove inhibitors of DNA and RNA polymerases, such as heme and the metabolic precursors of heme. Many different extraction protocols are used in both commercial and laboratory-developed amplification tests to remove inhibitors and purify nucleic acids (<link linkend="ch0101s0014s0003li0025">25</link>). Plasma is obtained by centrifuging blood collected in tubes containing spray-dried anticoagulant (EDTA) at 1,500 × <emphasis>g</emphasis> for 20 min at 25°C. Plasma preparation tubes (PPT; Becton-Dickinson [BD], Franklin Lakes, NJ) have spray-dried EDTA and a gel barrier that results in physical separation of plasma and cellular constituents, eliminating the need for decanting plasma. The use of PPT for HIV-1 RNA quantitation has shown falsely elevated viral loads from centrifuged tubes that were stored frozen or for prolonged periods at 2 to 8°C (<link linkend="ch0101s0014s0003li0053">53</link>–<link linkend="ch0101s0014s0003li0055">55</link>), likely due to the presence of cells containing proviral DNA (<link linkend="ch0101s0014s0003li0056">56</link>, <link linkend="ch0101s0014s0003li0057">57</link>). This limitation can be overcome by an additional centrifugation step prior to testing or use of an extraction method that recovers only RNA (<link linkend="ch0101s0014s0003li0058">58</link>, <link linkend="ch0101s0014s0003li0059">59</link>). No decline in hepatitis C virus RNA levels was observed in blood stored in PPT at 4°C for 72 h (<link linkend="ch0101s0014s0003li0060">60</link>).</para>
      <anchor id="ch0101s0003a0003"/>
      <beginpage pagenum="1627"/>
      <para id="ch0101s0003p0004">When serum is required for serologic or molecular testing, 4 to 8 ml of blood is collected in a serum separator tube (e.g., SST [BD Diagnostics], Corvac [Medtronic], or Vacuette [Greiner Bio-One]) or a tube without anticoagulant. After blood has been allowed to coagulate for 30 min, tubes are centrifuged at 1,000 to 1,300 ×<emphasis>g</emphasis> for 10 min. The serum fraction, removed to a sterile tube, can be stored at 2 to 8°C for up to 48 h or frozen at –20°C or lower for longer periods. Whole blood drawn for antibody determination should not be frozen.</para>
      <para id="ch0101s0003p0005">For virus culture, 5 to 10 ml of anticoagulated blood (EDTA or heparin) should be collected by venipuncture and transported to the laboratory at room temperature. Processing of the specimen for leukocyte fractionation should occur within 8 h. Whole blood should not be used to inoculate cell cultures because of toxicity caused by red blood cells. The buffy coat fraction may also contain erythrocytes. To adequately remove red blood cells and recover both polynuclear and mononuclear cells for inoculation, density gradient methods should be used; a number of density gradient testing kits are commercially available (<link linkend="ch0101s0014s0003li0023">23</link>). Isolated leukocytes can be cocultured with human diploid fibroblasts, such as MRC-5 cells (tube or shell vial culture) or H&amp;V Mix FreshCells (Diagnostic Hybrids) (shell vial culture) (<link linkend="ch0101s0014s0003li0061">61</link>), directly stained with fluorescence-labeled monoclonal antibodies (e.g., CMV pp65 antigenemia assay) (<link linkend="ch0101s0014s0003li0062">62</link>), or extracted to detect viral genomes by molecular techniques. Quantifying leukocyte input is essential for optimizing assay performance and for ensuring interrun quantitative quality control (<link linkend="ch0101s0014s0003li0063">63</link>, <link linkend="ch0101s0014s0003li0064">64</link>). For recovery of CMV in culture, the shell vial technique is more rapid and sensitive than conventional tube culture (<link linkend="ch0101s0014s0003li0065">65</link>).</para>
    </sect1>
    <sect1 id="ch0101s0004">
      <title>Bone Marrow</title>
      <anchor id="ch0101s0004a0001"/>
      <anchor id="ch0101s0004a0002"/>
      <para id="ch0101s0004p0001">Bone marrow can be used to identify viral etiologies of hematologic disorders, including hemophagocytic lymphohistiocytosis, aplastic anemia, and chronic pure red cell aplasia (<link linkend="ch0101s0014s0003li0066">66</link>, <link linkend="ch0101s0014s0003li0067">67</link>) (<link linkend="ch0101s0001s0002a0006">Table 1</link>). At least 2 ml of bone marrow aspirate should be collected in the appropriate anticoagulant tube. The recommended anticoagulants for NAATs include EDTA and ACD (<link linkend="ch0101s0014s0003li0025">25</link>). Although the diagnostic yield may be low, bone marrow aspirates for culture should be collected in a syringe or vacuum tube with heparin or EDTA and processed to fractionate the leukocytes as soon as possible after collection (<link linkend="ch0101s0014s0003li0068">68</link>, <link linkend="ch0101s0014s0003li0069">69</link>). Bone marrow specimens should be stored at 2 to 8°C prior to NA extraction. Freezing and thawing of bone marrow lyses red cells, causing release of heme, which may inhibit NA amplification, depending on the extraction procedure and amplification technique (<link linkend="ch0101s0014s0003li0070">70</link>).</para>
    </sect1>
    <sect1 id="ch0101s0005">
      <title>Cerebrospinal Fluid</title>
      <anchor id="ch0101s0005a0001"/>
      <anchor id="ch0101s0005a0002"/>
      <para id="ch0101s0005p0001">CSF is an important specimen for diagnosis of viral central nervous system infections (<link linkend="ch0101s0001s0002a0006">Table 1</link>). CSF is collected using a sterile technique, by inserting a spinal needle into the L4-L5 interspace, located in the midline between the left and right iliac crest. Preferably, 2 to 5 ml should be collected in a sterile, leakproof container. CSF samples should not be centrifuged prior to NA extraction, as many viruses are cell associated. VTM is not added to sterile body fluids such as CSF, since they do not require antimicrobial treatment and dilution in transport media may cause false-negative results. Samples should be transported and stored up to 48 h at 2 to 8°C and frozen at ≤–70°C for longer-term storage. Nucleic acids should typically be extracted prior to testing, since CSF contains globulins, cell-derived proteins, and other uncharacterized substances that inhibit the activity of thermostable polymerases used in PCR (<link linkend="ch0101s0014s0003li0071">71</link>, <link linkend="ch0101s0014s0003li0072">72</link>). However, some studies have demonstrated the suitability of simple methods, such as exposure to high temperature or repetitive freeze-thawing, to release nucleic acids (<link linkend="ch0101s0014s0003li0073">73</link>, <link linkend="ch0101s0014s0003li0074">74</link>). For virus culture, specimens with visible blood may affect recovery of viruses, since antibodies may be present in sufficient concentration to inhibit viral growth. No treatment of CSF is needed before inoculation of cell cultures.</para>
      <anchor id="ch0101s0005a0003"/>
      <beginpage pagenum="1628"/>
    </sect1>
    <sect1 id="ch0101s0006">
      <title>Dried Blood Spots</title>
      <anchor id="ch0101s0006a0001"/>
      <anchor id="ch0101s0006a0002"/>
      <para id="ch0101s0006p0001">The use of dried blood spots (DBS) eliminates the need for venipuncture and allows greater flexibility in storage temperature and transport time. DBS samples have been used in NA tests for diagnosis and monitoring of HIV infection, HBV quantification and genotyping, neonatal HSV infection, and detection of congenital CMV infection. Antibodies to viruses such as hepatitis A virus (HAV), HBV, HCV, Epstein-Barr virus (EBV), measles virus, and rubella virus can be detected in DBS, although the performance characteristics vary compared to those of serum testing, depending on the virus. DBS card samples can be prepared from a few drops of blood, typically 15 to 200 μl, obtained from a capillary blood stab, i.e., a finger prick (<link linkend="ch0101s0014s0003li0075">75</link>). A minimum of 2 h is needed for air drying of the blood spot. Once dried, DBS should be placed in hermetically sealed bags or containers with sufficient desiccant to minimize moisture exposure, which could allow growth of microorganisms (<link linkend="ch0101s0014s0003li0025">25</link>). DBS may be transported and stored at room temperature for relatively long periods (depending on the virus) or frozen at –20°C or lower for longer-term storage. Disks punched out from DBS cards normally contain the equivalent of 3.1 to 12.4 μl of blood depending on the punch size (3 to 6 mm) (<link linkend="ch0101s0014s0003li0075">75</link>). Once dried, HIV-1 RNA in a DBS is stable at ambient temperature or –70°C for at least 1 year, and the virus is typically inactivated (<link linkend="ch0101s0014s0003li0076">76</link>). Compared to plasma, more than 90% of finger-stick DBS samples from solid-organ transplant recipients showed less than a 1-log<subscript>10</subscript> deviation in CMV viral load, and the kinetics of CMV viral load during antiviral therapy were comparable (<link linkend="ch0101s0014s0003li0077">77</link>). In that study, the 95% limit of detection of CMV in DBS was estimated at 2,700 copies/ml (675 IU/ml).</para>
    </sect1>
    <sect1 id="ch0101s0007">
      <title>Eye</title>
      <anchor id="ch0101s0007a0001"/>
      <anchor id="ch0101s0007a0002"/>
      <para id="ch0101s0007p0001">Eye specimens include swabs or scrapings of the conjunctiva, corneal scrapings, and vitreous and aqueous fluids. Conjunctiva should be cleared of any exudate present with a swab before a specimen is collected. With a second flexible, fine-shafted Dacron or rayon swab premoistened with sterile saline, infected cells from the clean conjunctiva can be obtained and transferred to a vial of VTM or used to prepare a slide for immunofluorescent staining. The AdenoPlus test (Rapid Pathogen Screening, Inc., Sarasota, FL), a lateral-flow immunochromatographic cartridge test for the detection of ocular adenovirus infection, uses a built-in sampling pad to touch the eye and collect fluid from the conjunctiva. The sensitivity of the AdenoPlus test has been reported to be 85%, with a specificity of 98%, compared to PCR (<link linkend="ch0101s0014s0003li0078">78</link>). Corneal scrapings and swabbing of the cornea are best collected and placed in VTM by a specially trained clinician. Thin smears may be made directly from scrapings or swab specimens for use in immunofluorescent staining. Retinal pathogens are detected in the aqueous and vitreous fluids by NA testing, since they are not easily cultivated from these samples. Direct testing of these surgically obtained fluids has resulted in PCR inhibition (<link linkend="ch0101s0014s0003li0079">79</link>); therefore, the original specimen may need to be extracted. Should intraocular fluids not meet the minimum volume requirements for testing, it may be necessary to dilute samples with sterile saline or VTM to obtain sufficient volume for NA extraction. Result reports of diluted fluid specimens should include a comment indicating that test sensitivity and specificity are not established.</para>
      <beginpage/>
    </sect1>
    <sect1 id="ch0101s0008">
      <title>Genital</title>
      <anchor id="ch0101s0008a0001"/>
      <anchor id="ch0101s0008a0002"/>
      <para id="ch0101s0008p0001">The most common viral causes of genital lesions are HSV-1 and -2, which are detected by direct Ag assay (direct fluorescent-antibody assay [DFA]), NAATs, or culture. MPOX may also be on the differential for genital lesions, particularly for gay, bisexual, and other men who have sex with men, as was observed during the 2022 global MPOX outbreak; testing is primarily via NAAT. Cells and fluid from genital lesions are collected and processed as lesions from skin (discussed below).</para>
      <para id="ch0101s0008p0002">Testing of human papillomavirus (HPV) genotypes (i.e., genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) associated with a high risk of developing cervical cancer is performed using molecular methods on cervical specimens collected with swabs or brushes (detailed in<ulink url="ch0127#ch0127s0001">chapter 108</ulink>). Specimens may be collected in manufacturer-specific systems or FDA-approved/cleared liquid-based cytology solutions used concomitantly for Pap smear preparation. Freshly collected cervical biopsy samples, at least 2 to 5 mm in cross section, may be analyzed in some commercially available NAATs. All specimens should be placed immediately into the specimen transport medium provided by the assay manufacturer and stored, transported, and processed according to the manufacturer’s directions. Patient-collected cervicovaginal swab or lavage specimens (<link linkend="ch0101s0014s0003li0080">80</link>–<link linkend="ch0101s0014s0003li0083">83</link>) and swabs of penile lesions (<link linkend="ch0101s0014s0003li0084">84</link>, <link linkend="ch0101s0014s0003li0085">85</link>) have also proven reliable for detection of infection with high-risk HPV genotypes. Anal specimens for HPV testing can be collected using a saline-moistened Dacron swab and transported in liquid-based cytology media (<link linkend="ch0101s0014s0003li0086">86</link>, <link linkend="ch0101s0014s0003li0087">87</link>).</para>
      <para id="ch0101s0008p0003">Cervical brush specimens in standard transport medium for the HC2 High-Risk HPV DNA Test (Qiagen) may be stored for up to 2 weeks at room temperature, after which they can be stored for an additional week at 2 to 8°C or at –20°C for up to 3 months. Specimens in PreservCyt liquid-based cytology medium (Hologic, Bedford, MA) may be held at 2 to 30°C for up to 3 months for HC2 testing, and at 2 to 30°C for up to 6 months for cobas HPV (Roche Diagnostics, Indianapolis, IN) testing. For the Aptima HPV assay (Hologic, San Diego, CA), cervical specimens in ThinPrep Pap test vials containing PreservCyt solution should be transported and stored at 2 to 30°C with no more than 30 days at temperatures above 8°C and, for longer storage, at –20°C for up to 24 months. PreservCyt specimens cannot be frozen prior to testing for high-risk HPV genotypes. Specimens collected in SurePath preservative fluid (BD Diagnostics–TriPath, Burlington, NC) may be stored at 2 to 8°C for up to 6 months, or at 15 to 30°C for up to 4 weeks after the date of collection for cobas HPV (Roche Diagnostics, Indianapolis, IN) testing. Other methods of testing for high-risk HPV genotypes have not been FDA cleared/approved for use with specimens collected in SurePath preservative fluid.</para>
    </sect1>
    <sect1 id="ch0101s0009">
      <title>Oral</title>
      <anchor id="ch0101s0009a0001"/>
      <anchor id="ch0101s0009a0002"/>
      <para id="ch0101s0009p0001">An oral specimen provides a noninvasive means of detecting infection, and for some viruses, the onset of salivary shedding can indicate recent acquisition. Different types of oral specimens, including oral mucosal cells (including lesions), whole saliva, glandular duct saliva (from parotid, sublingual, and submandibular glands), and oral mucosal transudate (OMT), can be used for both culture and NA testing methods (<link linkend="ch0101s0014s0003li0088">88</link>). Oral mucosal cells are dislodged with a swab or plastic spatula; the collection device is then placed in VTM for transport to the laboratory. Saliva is collected by initially tilting the head forward and catching fluid from the lower lip into a collection container and then by catching residual, expectorated fluid after 5 min (<link linkend="ch0101s0014s0003li0088">88</link>). Parotid gland saliva, useful for diagnosing infectious parotitis, is collected with a swab approximately 30 s after massaging the area between the cheek and teeth at the level of the ear (<link linkend="ch0101s0014s0003li0089">89</link>).</para>
      <para id="ch0101s0009p0002">Salivary gland fluid consists primarily of secretory IgA (sIgA), whereas OMT contains a mixture of sIgA, IgG, and IgM. OMT (also called gingival crevicular fluid, crevicular fluid saliva, or crevicular fluid) arises from the capillaries in the buccal mucosa and the base of the pockets between the teeth and gums (gingival crevices) and can be collected with commercially available devices and transported to the laboratory at 2 to 8°C (<link linkend="ch0101s0014s0003li0090">90</link>). OMT has been used for detection of both IgM and IgG antibodies to measles virus, mumps virus, rubella virus, HIV, and hepatitis viruses (<link linkend="ch0101s0014s0003li0091">91</link>–<link linkend="ch0101s0014s0003li0093">93</link>). The performance characteristics of oral fluid for determination of antibodies to HIV and HCV approach those of blood-based specimens (<link linkend="ch0101s0014s0003li0094">94</link>, <link linkend="ch0101s0014s0003li0095">95</link>). However, HIV antibody testing with oral fluid alone is not recommended for patients at high risk of infection, particularly in low-prevalence settings, and should be followed by testing of a blood specimen (<link linkend="ch0101s0014s0003li0095">95</link>).</para>
      <para id="ch0101s0009p0003">Saliva samples are also collected for virus culture and NAAT, primarily for the evaluation of congenital CMV in the neonatal period. In this context, saliva has been shown to be comparable to urine for the diagnosis of congenital CMV using both shell vial culture and NAAT (<link linkend="ch0101s0014s0003li0096">96</link>). Though not typically used for the diagnosis of respiratory viruses, saliva has been utilized as an alternative to nasopharyngeal swabs for SARS-CoV-2 NAAT (<link linkend="ch0101s0014s0003li0097">97</link>).</para>
    </sect1>
    <sect1 id="ch0101s0010">
      <title>Respiratory</title>
      <anchor id="ch0101s0010a0001"/>
      <anchor id="ch0101s0010a0002"/>
      <para id="ch0101s0010p0001">Viruses causing upper respiratory tract (URT) and lower respiratory tract (LRT) infections can be detected using Ag detection, culture, and NAAT (<link linkend="ch0101s0001s0002a0006">Table 1</link>). Ideally, diagnostic testing should be completed within a time frame (generally 24 h) that allows the results to be used in patient management (<link linkend="ch0101s0014s0003li0098">98</link>).</para>
      <para id="ch0101s0010p0002">The primary site of replication for many respiratory viruses is the ciliated epithelial cells of the posterior nasopharynx and, to a lesser extent, the anterior nares and oropharynx. Therefore, nasal and throat specimens may not be acceptable for virus detection due to the fact that many viruses are present at low levels in these sites. However, these specimens may be suitable for use in highly sensitive NAATs or when immunocompromised patients may be at risk of bleeding with harsher collection methods. Anterior nares and nasal midturbinate as well as oropharyngeal swabs have also been extensively used during the COVID-19 pandemic for the diagnosis of SARS-CoV-2 infection (<link linkend="ch0101s0014s0003li0097">97</link>, <link linkend="ch0101s0014s0003li0099">99</link>).</para>
      <anchor id="ch0101s0010a0003"/>
      <beginpage pagenum="1629"/>
      <beginpage/>
      <para id="ch0101s0010p0003">An NP aspirate is collected by inserting a narrow catheter or tube through the nostril into the posterior nasopharynx. A mucus trap or syringe is connected to the other end, and suction is applied while the tube is slowly withdrawn back through the nostril. Any secretions remaining in the tubing should be flushed into the trap or syringe by aspirating VTM or sterile saline (<link linkend="ch0101s0014s0003li0022">22</link>, <link linkend="ch0101s0014s0003li0023">23</link>). A nasal wash is collected by instilling several milliliters of sterile saline into the nasal cavity using a bulb or syringe with catheter tubing attached. The contents are immediately aspirated by releasing the bulb or pulling the syringe plunger, and placed into a tube containing VTM or sterile container. Nasal washes can yield high rates of respiratory virus detection by NA testing with minimal patient discomfort compared to swab, aspirate, and brush sampling (<link linkend="ch0101s0014s0003li0100">100</link>).</para>
      <para id="ch0101s0010p0004">Swabs for respiratory virus testing should be polyester, Dacron, or rayon with plastic or aluminum shafts. Wooden-shaft swabs may contain substances that are toxic to eukaryotic cells. Calcium alginate swabs should not be used, since they may impair recovery of enveloped viruses, may interfere with fluorescent-antibody tests, and are inhibitory to some NAATs. Flocked swabs, made from nylon fiber using a proprietary spray-on technology, are designed for optimum specimen absorption and release and have been shown to collect more respiratory epithelial cells than conventional rayon swabs for DFA testing of respiratory viruses (<link linkend="ch0101s0014s0003li0101">101</link>, <link linkend="ch0101s0014s0003li0102">102</link>). Midturbinate flocked swabs are designed with a tapered cone shape, a sampling depth indication gauge, and a greater length and diameter of flocked nylon compared to regular swabs in order to sample a larger surface area of respiratory mucosa, including the inferior and middle turbinate bones. These can be self-collected; they yield numbers of respiratory epithelial cells comparable to those obtained with nasal and NP swabs and, in children, compared favorably with NP aspirates for DFA detection of common respiratory viruses (<link linkend="ch0101s0014s0003li0103">103</link>, <link linkend="ch0101s0014s0003li0104">104</link>). Polyurethane foam-tipped swabs provide an alternative to nylon or Dacron swabs for sampling of the anterior nares in patients who might be at risk for bleeding. Self-collected foam nasal swabs have been shown to be more sensitive than nasal washes for detection of several respiratory viruses by NAAT in immunocompromised patients, and they performed better than flocked nylon swabs for rapid influenza virus antigen testing in children (<link linkend="ch0101s0014s0003li0105">105</link>, <link linkend="ch0101s0014s0003li0106">106</link>).</para>
      <para id="ch0101s0010p0005">A swab of the posterior nasopharynx typically yields more virus than a swab of the anterior nares or throat. Here, the flexible, fine-tipped swab is inserted through the nostril along the floor of the nose into the nasopharynx until resistance is felt, then rotated several times, removed, and placed in VTM (<link linkend="ch0101s0014s0003li0023">23</link>). The swab should be pointed towards the ear rather than towards the top of the head and traverse half the distance between the angles of the nares and pinna. For DFA or NA testing, the sensitivity of flocked NP swabs for detection of respiratory viruses compares favorably to that of nasal wash and NP aspirate specimens (<link linkend="ch0101s0014s0003li0107">107</link>, <link linkend="ch0101s0014s0003li0108">108</link>). Throat swabs alone are generally inferior specimens for diagnosis of URT infections. However, combined testing of throat swabs with either NP swabs or aspirates can improve the yield of diagnostic etiologies of respiratory infection, as can the testing or pooling of other types of respiratory specimens (<link linkend="ch0101s0014s0003li0107">107</link>, <link linkend="ch0101s0014s0003li0109">109</link>, <link linkend="ch0101s0014s0003li0110">110</link>). Throat swabs are collected by depressing the tongue and swabbing the tonsillar area and posterior pharynx thoroughly.</para>
      <para id="ch0101s0010p0006">Although the oropharynx and nasopharynx are common portals for the introduction of viruses into the respiratory tract, the presence or absence of a virus in the URT may not be sufficient evidence of LRT disease, as evidenced by cases of influenza or SARS-CoV-2 infection in which URT samples tested negative for the presence of virus, while those from the LRT had detectable virus (<link linkend="ch0101s0014s0003li0111">111</link>, <link linkend="ch0101s0014s0003li0112">112</link>, <link linkend="ch0101s0014s0003li0113">113</link>). Similarly, SARS-CoV-1 and Middle Eastern respiratory syndrome (MERS) coronavirus may be detected with greater sensitivity in the LRT than the URT (<link linkend="ch0101s0014s0003li0114">114</link>). BAL specimens are collected by inserting a fiber-optic bronchoscope into the involved segment of the lung, instilling saline, and applying suction to remove the lavage specimen. BAL specimens for NA testing should be transported and tested within 24 h of collection, stored at 4°C for up to 72 h, or frozen at ≤–70°C for future testing (<link linkend="ch0101s0014s0003li0025">25</link>). Traditionally, sputum has been considered a suboptimal specimen for virus culture. However, sputum may be a suitable specimen for respiratory virus detection using NAATs (reviewed in reference <link linkend="ch0101s0014s0003li0115">115</link>) and has been shown to increase the diagnostic yield over combined nasal and throat specimens in adults with respiratory illness (<link linkend="ch0101s0014s0003li0116">116</link>). However, in children with radiologic evidence of pneumonia, respiratory pathogen NAAT of induced sputum was shown to have limited diagnostic utility (<link linkend="ch0101s0014s0003li0117">117</link>). Furthermore, it is possible that viruses identified in sputum may not necessarily represent LRT infection, since they may originate in the oropharynx. Sputum for NAATs should be collected in a sterile container and transported to the laboratory at room temperature within 30 min or, if the transportation time is longer, transported at 4°C (<link linkend="ch0101s0014s0003li0025">25</link>).</para>
      <para id="ch0101s0010p0007">Respiratory fluids (e.g., NP aspirates and nasal washes) or swabs in VTM for culture should be vortexed to release cell-associated virus and centrifuged at 500 to 1,000 ×<emphasis>g</emphasis> for 10 min unless there is a minimal amount of cellular debris. The supernatant can be used directly as the inoculum or further clarified by filtration (0.45-μm pore size) to remove any additional bacterial, fungal, and/or cellular debris. The pelleted cells (washed two or three times in phosphate-buffered saline) may be used for immunofluorescent (IF) staining (<link linkend="ch0101s0014s0003li0022">22</link>, <link linkend="ch0101s0014s0003li0023">23</link>). Application of the concentrated cell suspension to a slide by cytospin preparation can increase the sensitivity of IF staining and reduce the number of inadequate specimens (<link linkend="ch0101s0014s0003li0118">118</link>). It is not necessary to centrifuge or filter specimens for Ag or NA detection, since these assays should not be affected by microbial contamination. In fact, the loss of host cells may compromise the sensitivity of Ag and NA tests.</para>
      <para id="ch0101s0010p0008">Mucus in respiratory specimens can significantly affect Ag detection. In DFA tests, mucus can inhibit adherence of cells to slides and can cause nonspecific fluorescence. It also prevents penetration of the sample into filtration devices. To prevent these complications, mucus threads can be broken by repeated aspiration through a small-bore pipette. Specimens with excessive mucus can be centrifuged at 900 ×<emphasis>g</emphasis> for 5 min with removal of the mucus layer above the cell pellet, or treated with 2% dimercaptoethanol with incubation at room temperature for 10 min prior to centrifugation.</para>
    </sect1>
    <sect1 id="ch0101s0011">
      <title>Skin</title>
      <anchor id="ch0101s0011a0001"/>
      <anchor id="ch0101s0011a0002"/>
      <para id="ch0101s0011p0001">Viruses can cause rashes with many different appearances, including maculopapular, petechial, and vesicular rashes. Recovery of viruses from maculopapular and petechial rashes requires biopsy of skin, which is not routinely performed. Viral causes of disseminated diseases manifested by maculopapular and petechial rashes are usually identified by their clinical features and laboratory testing of specimen types other than skin, often blood for serologic or NA testing (<link linkend="ch0101s0001s0002a0006">Table 1</link>), since the virions are not typically found in lesions resulting from the host immune response to infection (<link linkend="ch0101s0014s0003li0119">119</link>).</para>
      <anchor id="ch0101s0011a0003"/>
      <beginpage pagenum="1630"/>
      <para id="ch0101s0011p0002">Vesicular lesions are commonly caused by HSV, VZV, and enteroviruses. Cells and fluid from fresh vesicles are preferred over other lesion types, such as pustules, ulcers, and crusts, which may not contain sufficient virus for Ag detection, NA testing, or culture. Vesicular fluid can be collected by use of capillary pipettes or syringes or on swabs placed in VTM. Vesicles which have not been opened may have fluid contents withdrawn by means of a sterile tuberculin syringe fitted with a 26- or 27-gauge needle. Prior preparation of the area with disinfectants such as iodophors or alcohol may inactivate the viruses. Therefore, local disinfection should be used after the specimen has been collected. Fluids collected by syringe aspiration should be rinsed promptly into VTM. Alternatively, vesicles may be uncapped using a sterile needle or scalpel and the vesicle fluids adsorbed onto the tip of a sterile swab and placed in VTM. The margins and base of the lesion should be swabbed briskly to obtain infected epithelial cells (<link linkend="ch0101s0014s0003li0022">22</link>). Cells from ulcers or crusted lesions (after removal of the crust) should be collected by rolling a swab over the same area. Specimens should be collected without causing bleeding, since the presence of neutralizing antibody in blood can impair recovery. Smears for immunofluorescent staining (e.g., for HSV and VZV) can be prepared at the patient’s bedside by spreading the material thinly onto a small area in the center of a clean slide. After air drying, slides should be fixed in acetone for 5 to 10 min prior to staining. Swabs or vesicle fluid in VTM can be tested by NAATs, Ag detection, and/or culture. Specimens for viral culture can be inoculated directly after vortexing, or first clarified by centrifugation and filtration if debris is present. MPOX testing may also be considered for vesicular lesions under appropriate epidemiologic conditions. Collection and transport recommendations should be confirmed with the reference laboratory.</para>
    </sect1>
    <sect1 id="ch0101s0012">
      <title>Stool and Rectal Swabs</title>
      <anchor id="ch0101s0012a0001"/>
      <anchor id="ch0101s0012a0002"/>
      <para id="ch0101s0012p0001">Stool is the optimal specimen for identification of viruses causing gastroenteritis. Many gastroenteritis viruses (e.g., rotavirus) are noncultivable and require Ag or NA tests for detection. Ideally, specimens should be collected within the first 2 to 4 days of illness, since detection rates are reduced in later stages of infection unless the patient’s underlying condition allows prolonged shedding. However, most enteroviruses can be recovered in stool for several weeks after onset of symptomatic infection.</para>
      <para id="ch0101s0012p0002">Approximately 2 to 5 ml of liquid stool or 2 to 5 g of formed stool should be collected in a clean, dry, leakproof container or in VTM, depending on the type of testing to be performed. Fresh stool specimens can be stored at 4°C for 2 to 3 days if they are not tested immediately after collection. For prolonged storage, specimens should be kept frozen, preferably at ≤–70°C. Specially formulated paper strips have also been used for collection, transport, and storage of stool samples for NA testing of rotavirus, adenovirus types 40 and 41, and norovirus (<link linkend="ch0101s0014s0003li0043">43</link>, <link linkend="ch0101s0014s0003li0044">44</link>, <link linkend="ch0101s0014s0003li0120">120</link>). The rectal swab is generally considered an inferior specimen to stool, as it usually collects an insufficient amount of specimen; the utility is directly related to the amount of visible stool collected. For collection, the swab is inserted several centimeters past the anal sphincter, rotated for several seconds, removed, and placed in VTM.</para>
      <para id="ch0101s0012p0003">As bacteria comprise a significant proportion of the mass of stool, centrifugation, filtration, or both are often necessary to prevent microbial contamination of cell cultures. For virus culture, a 10 to 20% (wt/vol) stool suspension is prepared in VTM with antimicrobials and glass beads and vortexed for 1 min, and the suspension is centrifuged at 3,000 ×<emphasis>g</emphasis> for 15 to 30 min. The clarified supernatant can be filtered through a 0.2- to 0.45-μm pore size filter prior to inoculation of cell cultures (<link linkend="ch0101s0014s0003li0022">22</link>, <link linkend="ch0101s0014s0003li0023">23</link>).</para>
    </sect1>
    <sect1 id="ch0101s0013">
      <title>Tissue (Biopsy or Autopsy)</title>
      <anchor id="ch0101s0013a0001"/>
      <anchor id="ch0101s0013a0002"/>
      <para id="ch0101s0013p0001">Tissue specimens obtained during surgery or at autopsy can be assessed by several diagnostic methods. Lung, liver, lymph node, kidney, spleen, cardiac, and brain tissue can be used to identify the viral etiology of many clinical syndromes (<link linkend="ch0101s0001s0002a0006">Table 1</link>). Due to the invasive nature of specimen collection, the laboratory should ensure that a sufficient quantity of tissue is available for all testing requested; otherwise, testing can be prioritized by the clinician. The tissue can be divided in the laboratory in consultation with the pathologist to determine which portions should be submitted for viral diagnostics (<link linkend="ch0101s0014s0003li0121">121</link>). A small piece of tissue from the leading edge of the affected area should be excised and kept moist in a sterile container, typically with sterile saline if comprehensive microbiologic and histologic testing is requested. Formalin-fixed tissue is unsuitable for viral culture, and formalin may affect the performance of NAATs, though successful detection of both DNA and RNA viruses in formalin-fixed tissues has been reported (<link linkend="ch0101s0014s0003li0025">25</link>, <link linkend="ch0101s0014s0003li0122">122</link>–<link linkend="ch0101s0014s0003li0124">124</link>). Touch preparations of cells can be made by pressing tissue against the clean surface of a glass slide multiple times. Once air dried, the slide is fixed in acetone prior to application of staining reagents.</para>
      <para id="ch0101s0013p0002">If NA is to be extracted, biopsy samples or large tissue specimens should be kept moist with sterile normal saline or placed in a suitable nucleic acid preservative. While the stability of NAs in tissue specimens varies with tissue type, it is recommended that tissues be transported to the laboratory on wet ice or frozen (<link linkend="ch0101s0014s0003li0025">25</link>). Fresh tissue specimens for NA detection are minced, treated with proteolytic enzymes, and extracted. Formalin-fixed, paraffin-embedded tissues for NA testing should be stored and transported at ambient temperatures, deparaffinized, and extracted. However, fresh tissue is superior for NA recovery, since formalin treatment induces considerable nucleic acid degradation (<link linkend="ch0101s0014s0003li0025">25</link>). For viral culture from tissue, the recommended method is to prepare a 10 to 20% (wt/vol) homogenate, using VTM as a diluent, from small or minced tissue fragments that have been aseptically ground in a tissue grinder (<link linkend="ch0101s0014s0003li0022">22</link>, <link linkend="ch0101s0014s0003li0023">23</link>). The homogenate can be centrifuged (600 to 900 × <emphasis>g</emphasis> for 10 min) or allowed to settle by gravity, and the supernatant is then used as the inoculum.</para>
    </sect1>
    <sect1 id="ch0101s0014">
      <title>Urine</title>
      <anchor id="ch0101s0014a0001"/>
      <anchor id="ch0101s0014a0002"/>
      <para id="ch0101s0014p0001">Urine specimens should be collected as soon as possible after the onset of illness or when congenital or perinatal infection is first suspected. A volume of 5 to 10 ml of urine (midstream or catheter obtained) is collected in a sterile container; no VTM is required. The nature and timing of the collection are not known to have any effect on the reliability of testing methods. For NAATs, ambient storage of fresh unprocessed urine should be minimized, since the low pH and high urea content rapidly denature DNA/RNA (<link linkend="ch0101s0014s0003li0025">25</link>, <link linkend="ch0101s0014s0003li0125">125</link>). Nucleic acids should be extracted before testing, since urine contains substances that can inhibit PCR (<link linkend="ch0101s0014s0003li0126">126</link>–<link linkend="ch0101s0014s0003li0128">128</link>). Nucleic acids may be extracted from urine obtained on filter paper disks, or the disks may be used directly in the NAAT as a template without additional purification or elution steps (<link linkend="ch0101s0014s0003li0129">129</link>–<link linkend="ch0101s0014s0003li0131">131</link>).</para>
      <anchor id="ch0101s0014a0003"/>
      <beginpage pagenum="1631"/>
      <para id="ch0101s0014p0002">Prior to inoculation of cell culture, urine can be filtered (0.45-μm pore size) or centrifuged (1,000 ×<emphasis>g</emphasis> for 10 min) to remove bacteria and debris; the pH can be neutralized with sodium bicarbonate (7.5% solution) to reduce toxicity (<link linkend="ch0101s0014s0003li0023">23</link>). Alternatively, antibiotics can be added directly to the urine, or it can be diluted with VTM to neutralize pH and introduce antimicrobials (<link linkend="ch0101s0014s0003li0022">22</link>). The mixture should be allowed to stand at room temperature for 15 min prior to inoculation of cell cultures.</para>
      <sect2 id="ch0101s0014s0001">
        <title>TRANSPORTATION REGULATIONS</title>
        <anchor id="ch0101s0014s0001a0001"/>
        <anchor id="ch0101s0014s0001a0002"/>
        <para id="ch0101s0014s0001p0001">Shipment of specimens to reference or public health laboratories is common practice. All packages that contain infectious substances must meet the shipping regulations of various organizations or agencies. In the United States, the main source for regulations governing specimen and biological shipments is the U.S. Department of Transportation (DOT). The International Air Transport Association (IATA) regulates all shipments on air carriers and provides its own Dangerous Goods Regulations (DGR) (<link linkend="ch0101s0014s0003li0132">132</link>). Since there is some harmonization between the national and international regulatory bodies, the IATA requirements are usually acceptable under all regulations.</para>
        <para id="ch0101s0014s0001p0002">The DGR include specific instructions for packaging and labeling of shipments containing biological or infectious substances, such as patient specimens or cultured microorganisms (<link linkend="ch0101s0014s0003li0132">132</link>). In the clinical laboratory, materials being shipped generally fall into one of three categories: exempt human specimen, category A, or category B. Category A infectious substances (UN2814 infectious substance, affecting humans) are those transported in a form that, when exposure to it occurs, can cause potentially life-threatening illness (e.g., Ebola virus). The most up-to-date list of category A infectious substances can be found at the IATA website for Dangerous Goods Regulations (<ulink url="http://www.iata.org/whatwedo/cargo/dgr/Pages/download.aspx">www.iata.org/whatwedo/cargo/dgr/Pages/download.aspx</ulink>). An infectious substance that does not meet the criteria for inclusion in category A is assigned to category B (UN3373 biological substance, category B) unless it is a patient specimen for which there is minimal likelihood that pathogens are present, in which case it would be labeled an exempt human specimen.</para>
        <para id="ch0101s0014s0001p0003">For transportation of any category A infectious substance, packaging must include an inner container, an itemized list of contents, and an outer packaging. The inner packaging must comprise one or more leakproof primary receptacles and leakproof secondary packaging capable of withstanding an internal pressure differential of at least 95 kPa. For liquid specimens, an absorbent material in sufficient quantity to absorb the entire contents must be placed between the primary and secondary packaging. Category B packing instructions are essentially identical to those for category A, although no packing list needs be included. Exempt patient specimens are packaged with leakproof primary and secondary receptacles within an outer container of adequate strength. Training of personnel for packaging and shipping dangerous goods must be documented, and recertification is required every 2 years. The DOT may inspect any shipper or receiver of dangerous goods, unannounced, at any time.</para>
      </sect2>
      <sect2 id="ch0101s0014s0002">
        <title>SUMMARY</title>
        <anchor id="ch0101s0014s0002a0001"/>
        <anchor id="ch0101s0014s0002a0002"/>
        <para id="ch0101s0014s0002p0001">The importance of appropriate specimen collection and handling to ensure accurate laboratory results cannot be overstated, and the laboratory must serve as a resource for clinicians. In some instances, proper collection, transport, and processing of specimens are determined by the manufacturer, whereas laboratories which utilize in-house-developed tests need to verify these preanalytical factors themselves prior to routine clinical testing (<link linkend="ch0101s0014s0003li0045">45</link>).</para>
        <para id="ch0101s0014s0002p0002">The performance characteristics of viral diagnostic tests (sensitivity, specificity, positive predictive value, and negative predictive value) are, to a large extent, dependent on the integrity of viral or host components present in the specimen. For molecular methods, successful testing is based largely on the quality of the nucleic acid purified from the clinical specimen. That quality is directly related to how the specimen is stored and transported to the laboratory after it has been collected from the patient. Detection of viral antigens requires that adequate amounts of intact cellular material from the site of infection be collected and maintained to prevent degradation. Serologic testing is impacted by the timing of collection relative to disease progression. Successful recovery of virus in culture requires maintenance of replication competency, which can be enhanced by (i) the timing and method of collection to incorporate high titers of virus, (ii) protection from thermal inactivation or drying, and (iii) use of an effective transport system.</para>
      </sect2>
      <sect2 id="ch0101s0014s0003">
        <title>REFERENCES</title>
        <anchor id="ch0101s0014s0003a0001"/>
        <anchor id="ch0101s0014s0003a0002"/>
        <itemizedlist mark="none" role="biblioEntryList">
          <listitem id="ch0101s0014s0003li0001" role="bibliographyEntry">
            <para>1.<emphasis role="strong">Astion ML, Shojania KG, Hamill TR, Kim S, Ng VL.</emphasis> 2003. Classifying laboratory incident reports to identify problems that jeopardize patient safety. <citetitle><emphasis>Am J Clin Pathol</emphasis></citetitle> <emphasis role="strong">120:</emphasis>18–26.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0002" role="bibliographyEntry">
            <para>2.<emphasis role="strong">Grys TE, Smith TF.</emphasis> 2009. Specimen requirements: selection, collection, transport, and processing, p 18–35. <citetitle><emphasis>In</emphasis></citetitle> Specter SHR, Young SA, Wiedbrauk DL (ed), <citetitle><emphasis>Clinical Virology Manual</emphasis></citetitle>, 4th ed. ASM Press, Washington, DC.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0003" role="bibliographyEntry">
            <para>3.<emphasis role="strong">Graf EH, Simmon KE, Tardif KD, Hymas W, Flygare S, Eilbeck K, Yandell M, Schlaberg R.</emphasis> 2016. Unbiased detection of respiratory viruses by use of RNA sequencing-based metagenomics: a systematic comparison to a commercial PCR panel. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>1000–1007.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0004" role="bibliographyEntry">
            <para>4.<emphasis role="strong">Doan T, Acharya NR, Pinsky BA, Sahoo MK, Chow ED, Banaei N, Budvytiene I, Cevallos V, Zhong L, Zhou Z, Lietman TM, DeRisi JL.</emphasis> 2017. Metagenomic DNA sequencing for the diagnosis of intraocular infections. <citetitle><emphasis>Ophthalmology</emphasis></citetitle> <emphasis role="strong">124:</emphasis>1247–1248.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0005" role="bibliographyEntry">
            <para>5.<emphasis role="strong">Lau LLH, Cowling BJ, Fang VJ, Chan KH, Lau EHY, Lipsitch M, Cheng CKY, Houck PM, Uyeki TM, Peiris JSM, Leung GM.</emphasis> 2010. Viral shedding and clinical illness in naturally acquired influenza virus infections. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">201:</emphasis>1509–1516.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0006" role="bibliographyEntry">
            <para>6.<emphasis role="strong">Milano F, Campbell AP, Guthrie KA, Kuypers J, Englund JA, Corey L, Boeckh M.</emphasis> 2010. Human rhinovirus and coronavirus detection among allogeneic hematopoietic stem cell transplantation recipients. <citetitle><emphasis>Blood</emphasis></citetitle> <emphasis role="strong">115:</emphasis>2088–2094.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0007" role="bibliographyEntry">
            <para>7.<emphasis role="strong">Milbrath MO, Spicknall IH, Zelner JL, Moe CL, Eisenberg JN.</emphasis> 2013. Heterogeneity in norovirus shedding duration affects community risk. <citetitle><emphasis>Epidemiol Infect</emphasis></citetitle> <emphasis role="strong">141:</emphasis>1572–1584.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0008" role="bibliographyEntry">
            <para>8.<emphasis role="strong">von Linstow ML, Eugen-Olsen J, Koch A, Winther TN, Westh H, Hogh B.</emphasis> 2006. Excretion patterns of human metapneumovirus and respiratory syncytial virus among young children. <citetitle><emphasis>Eur J Med Res</emphasis></citetitle> <emphasis role="strong">11:</emphasis>329–335.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0009" role="bibliographyEntry">
            <para>9.<emphasis role="strong">Walsh EE, Peterson DR, Kalkanoglu AE, Lee FE, Falsey AR.</emphasis> 2013. Viral shedding and immune responses to respiratory syncytial virus infection in older adults. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">207:</emphasis>1424–1432.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0010" role="bibliographyEntry">
            <para>10.<emphasis role="strong">Peiris JSM, Chu CM, Cheng VCC, Chan KS, Hung IFN, Poon LLM, Law KI, Tang BSF, Hon TYW, Chan CS, Chan KH, Ng JSC, Zheng BJ, Ng WL, Lai RWM, Guan Y, Yuen KY, HKU/UCH SARS Study Group.</emphasis> 2003. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">361:</emphasis>1767–1772.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0011" role="bibliographyEntry">
            <para>11.<emphasis role="strong">Centers for Disease Control and Prevention.</emphasis> 2004. <citetitle><emphasis>Public Health Guidance for Community-Level Preparedness and Response to Severe Acute Respiratory Syndrome (SARS).</emphasis></citetitle> US Department of Health and Human Services and CDC, Atlanta, GA.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0012" role="bibliographyEntry">
            <para>12.<emphasis role="strong">Siegel JD, Rhinehart E, Jackson M, Chiarello L, Health Care Infection Control Practices Advisory Committee.</emphasis> 2007. 2007 guideline for isolation precautions: preventing transmission of infectious agents in health care settings. <citetitle><emphasis>Am J Infect Control</emphasis></citetitle> <emphasis role="strong">35</emphasis>(Suppl 2)<emphasis role="strong">:</emphasis>S65–S164.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0013" role="bibliographyEntry">
            <para>13.<emphasis role="strong">Blow JA, Dohm DJ, Negley DL, Mores CN.</emphasis> 2004. Virus inactivation by nucleic acid extraction reagents. <citetitle><emphasis>J Virol Methods</emphasis></citetitle> <emphasis role="strong">119:</emphasis>195–198.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0014" role="bibliographyEntry">
            <para>14.<emphasis role="strong">Josephson SL.</emphasis> 1997. An update on the collection and transport of specimens for viral culture. <citetitle><emphasis>Clin Microbiol Newsl</emphasis></citetitle> <emphasis role="strong">19:</emphasis>57–61.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0015" role="bibliographyEntry">
            <para>15.<emphasis role="strong">Johnson FB.</emphasis> 1990. Transport of viral specimens. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">3:</emphasis>120–131.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0016" role="bibliographyEntry">
            <para>16.<emphasis role="strong">Druce J, Garcia K, Tran T, Papadakis G, Birch C.</emphasis> 2012. Evaluation of swabs, transport media, and specimen transport conditions for optimal detection of viruses by PCR. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>1064–1065.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0017" role="bibliographyEntry">
            <para>17.<emphasis role="strong">CLSI.</emphasis> 2013. Quality control of microbiological transport systems. Approved guideline. <citetitle><emphasis>CLSI document M40-A2.</emphasis></citetitle> CLSI, Wayne, PA.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0018" role="bibliographyEntry">
            <para>18.<emphasis role="strong">Dunn JJ, Billetdeaux E, Skodack-Jones L, Carroll KC.</emphasis> 2003. Evaluation of three Copan viral transport systems for the recovery of cultivatable, clinical virus isolates. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">45:</emphasis>191–197.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0019" role="bibliographyEntry">
            <para>19.<emphasis role="strong">Gleaves CA, Rice DH, Lee CF.</emphasis> 1990. Evaluation of an enzyme immunoassay for the detection of herpes simplex virus (HSV) antigen from clinical specimens in viral transport media. <citetitle><emphasis>J Virol Methods</emphasis></citetitle> <emphasis role="strong">28:</emphasis>133–139.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0020" role="bibliographyEntry">
            <para>20.<emphasis role="strong">Hodinka RL.</emphasis> 2009. Laboratory diagnosis of viral diseases, p 17–35. <citetitle><emphasis>In</emphasis></citetitle> Shah SS (ed), <citetitle><emphasis>Pediatric Practice: Infectious Disease.</emphasis></citetitle> McGraw-Hill, New York, NY.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0021" role="bibliographyEntry">
            <para>21.<emphasis role="strong">Hambling MH.</emphasis> 1964. Survival of the respiratory syncytial virus during storage under various conditions. <citetitle><emphasis>Br J Exp Pathol</emphasis></citetitle> <emphasis role="strong">45:</emphasis>647–655.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0022" role="bibliographyEntry">
            <para>22.<emphasis role="strong">Clarke L.</emphasis> 2010. Specimen collection and processing, p 10.4.1–10.4.11. <citetitle><emphasis>In</emphasis></citetitle> Garcia LS (ed), <citetitle><emphasis>Clinical Microbiology Procedures Handbook</emphasis></citetitle>, 3rd ed. ASM Press, Washington, DC.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0023" role="bibliographyEntry">
            <para>23.<emphasis role="strong">CLSI.</emphasis> 2006. Viral culture. Approved guideline. CLSI document M41-A. Clinical and Laboratory Standards Institute, Wayne, PA.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0024" role="bibliographyEntry">
            <para>24.<emphasis role="strong">Miller JM, Astles R, Baszler T, Chapin K, Carey R, Garcia L, Gray L, Larone D, Pentella M, Pollock A, Shapiro DS, Weirich E, Wiedbrauk D, Biosafety Blue Ribbon Panel, Centers for Disease Control and Prevention (CDC).</emphasis> 2012. Guidelines for safe work practices in human and animal medical diagnostic laboratories. Recommendations of a CDC-convened, Biosafety Blue Ribbon Panel. <citetitle><emphasis>MMWR Suppl</emphasis></citetitle> <emphasis role="strong">61</emphasis>(Suppl)<emphasis role="strong">:</emphasis>1–102.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0025" role="bibliographyEntry">
            <para>25.<emphasis role="strong">CLSI.</emphasis> 2020. Collection, transport, preparation, and storage of specimens for molecular methods. Approved guideline. 2nd ed. CLSI document MM13-ED2. Clinical and Laboratory Standards Institute, Wayne, PA.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0026" role="bibliographyEntry">
            <para>26.<emphasis role="strong">Ginocchio CC, Wang XP, Kaplan MH, Mulligan G, Witt D, Romano JW, Cronin M, Carroll R.</emphasis> 1997. Effects of specimen collection, processing, and storage conditions on stability of human immunodeficiency virus type 1 RNA levels in plasma. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">35:</emphasis>2886–2893.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0027" role="bibliographyEntry">
            <para>27.<emphasis role="strong">José M, Gajardo R, Jorquera JI.</emphasis> 2005. Stability of HCV, HIV-1 and HBV nucleic acids in plasma samples under long-term storage. <citetitle><emphasis>Biologicals</emphasis></citetitle> <emphasis role="strong">33:</emphasis>9–16.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0028" role="bibliographyEntry">
            <para>28.<emphasis role="strong">Watson J, Graves S, Ferguson J, D’Este C, Batey R.</emphasis> 2007. Hepatitis C virus RNA quantitation and degradation studies in whole blood samples in vitro. <citetitle><emphasis>Gut</emphasis></citetitle> <emphasis role="strong">56:</emphasis>306–307.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0029" role="bibliographyEntry">
            <para>29.<emphasis role="strong">Jennings C, Danilovic A, Scianna S, Brambilla DJ, Bremer JW.</emphasis> 2005. Stability of human immunodeficiency virus type 1 proviral DNA in whole-blood samples. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>4249–4250.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0030" role="bibliographyEntry">
            <para>30.<emphasis role="strong">Lee DH, Li L, Andrus L, Prince AM.</emphasis> 2002. Stabilized viral nucleic acids in plasma as an alternative shipping method for NAT. <citetitle><emphasis>Transfusion</emphasis></citetitle> <emphasis role="strong">42:</emphasis>409–413.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0031" role="bibliographyEntry">
            <para>31.<emphasis role="strong">Uhlenhaut C, Kracht M.</emphasis> 2005. Viral infectivity is maintained by an RNA protection buffer. <citetitle><emphasis>J Virol Methods</emphasis></citetitle> <emphasis role="strong">128:</emphasis>189–191.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0032" role="bibliographyEntry">
            <para>32.<emphasis role="strong">Blow JA, Mores CN, Dyer J, Dohm DJ.</emphasis> 2008. Viral nucleic acid stabilization by RNA extraction reagent. <citetitle><emphasis>J Virol Methods</emphasis></citetitle> <emphasis role="strong">150:</emphasis>41–44.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0033" role="bibliographyEntry">
            <para>33.<emphasis role="strong">Hasan MR, Tan R, Al-Rawahi GN, Thomas E, Tilley P.</emphasis> 2012. Short-term stability of pathogen-specific nucleic acid targets in clinical samples. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>4147–4150.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0034" role="bibliographyEntry">
            <para>34.<emphasis role="strong">Endler G, Slavka G.</emphasis> 2010. Stability of the specimen during preanalytics, p 25–34. <citetitle><emphasis>In</emphasis></citetitle> Kessler HH (ed), <citetitle><emphasis>Molecular Diagnostics of Infectious Diseases.</emphasis></citetitle> Walter de Gruyter and Co, New York, NY.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0035" role="bibliographyEntry">
            <para>35.<emphasis role="strong">Nesbitt SE, Cook L, Jerome KR.</emphasis> 2004. Cytomegalovirus quantitation by real-time PCR is unaffected by delayed separation of plasma from whole blood. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">42:</emphasis>1296–1297.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0036" role="bibliographyEntry">
            <para>36.<emphasis role="strong">Roberts TC, Buller RS, Gaudreault-Keener M, Sternhell KE, Garlock K, Singer GG, Brennan DC, Storch GA.</emphasis> 1997. Effects of storage temperature and time on qualitative and quantitative detection of cytomegalovirus in blood specimens by shell vial culture and PCR. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">35:</emphasis>2224–2228.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0037" role="bibliographyEntry">
            <para>37.<emphasis role="strong">Abdul-Ali D, Kraft CS, Ingersoll J, Frempong M, Caliendo AM.</emphasis> 2011. Cytomegalovirus DNA stability in EDTA anti-coagulated whole blood and plasma samples. <citetitle><emphasis>J Clin Virol</emphasis></citetitle> <emphasis role="strong">52:</emphasis>222–224.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0038" role="bibliographyEntry">
            <para>38.<emphasis role="strong">Schäfer P, Tenschert W, Schröter M, Gutensohn K, Laufs R.</emphasis> 2000. False-positive results of plasma PCR for cytomegalovirus DNA due to delayed sample preparation. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">38:</emphasis>3249–3253.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0039" role="bibliographyEntry">
            <para>39.<emphasis role="strong">Jerome KR, Huang ML, Wald A, Selke S, Corey L.</emphasis> 2002. Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">40:</emphasis>2609–2611.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0040" role="bibliographyEntry">
            <para>40.<emphasis role="strong">Wiedbrauk DL, Cunningham W.</emphasis> 1996. Stability of herpes simplex virus DNA in cerebrospinal fluid specimens. <citetitle><emphasis>Diagn Mol Pathol</emphasis></citetitle> <emphasis role="strong">5:</emphasis>249–252.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0041" role="bibliographyEntry">
            <para>41.<emphasis role="strong">Agreda PM, Beitman GH, Gutierrez EC, Harris JM, Koch KR, LaViers WD, Leitch SV, Maus CE, McMillian RA, Nussbaumer WA, Palmer MLR, Porter MJ, Richart GA, Schwab RJ, Vaughan LM.</emphasis> 2013. Long-term stability of human genomic and human papillomavirus DNA stored in BD SurePath and Hologic PreservCyt liquid-based cytology media. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>2702–2706.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0042" role="bibliographyEntry">
            <para>42.<emphasis role="strong">Fischer TK, Steinsland H, Valentiner-Branth P.</emphasis> 2002. Rotavirus particles can survive storage in ambient tropical temperatures for more than 2 months. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">40:</emphasis>4763–4764.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0043" role="bibliographyEntry">
            <para>43.<emphasis role="strong">Zlateva KT, Maes P, Rahman M, Van Ranst M.</emphasis> 2005. Chromatography paper strip sampling of enteric adenoviruses type 40 and 41 positive stool specimens. <citetitle><emphasis>Virol J</emphasis></citetitle> <emphasis role="strong">2:</emphasis>6.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0044" role="bibliographyEntry">
            <para>44.<emphasis role="strong">Wollants E, Maes P, Thoelen I, Vanneste F, Rahman M, Van Ranst M.</emphasis> 2004. Evaluation of a norovirus sampling method using sodium dodecyl sulfate/EDTA-pretreated chromatography paper strips. <citetitle><emphasis>J Virol Methods</emphasis></citetitle> <emphasis role="strong">122:</emphasis>45–48.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0045" role="bibliographyEntry">
            <para>45.<emphasis role="strong">Burd EM.</emphasis> 2010. Validation of laboratory-developed molecular assays for infectious diseases. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">23:</emphasis>550–576.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0046" role="bibliographyEntry">
            <para>46.<emphasis role="strong">CLSI.</emphasis> 2011. Establishing molecular testing in clinical laboratory environments. Approved guideline. CLSI document MM19-A. Clinical and Laboratory Standards Institute, Wayne, PA.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0047" role="bibliographyEntry">
            <para>47.<emphasis role="strong">Landini MP, Lazzarotto T.</emphasis> 1999. Prenatal diagnosis of congenital cytomegalovirus infection: light and shade. <citetitle><emphasis>Herpes</emphasis></citetitle> <emphasis role="strong">6:</emphasis>45–49.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0048" role="bibliographyEntry">
            <anchor id="ch0101s0014s0003a0003"/>
            <para>48.<emphasis role="strong">Mendelson E, Aboudy Y, Smetana Z, Tepperberg M, Grossman Z.</emphasis> 2006. Laboratory assessment and diagnosis of congenital viral infections: rubella, cytomegalovirus (CMV), varicella-zoster virus (VZV), herpes simplex virus (HSV), parvovirus B19 and human immunodeficiency virus (HIV). <citetitle><emphasis>Reprod Toxicol</emphasis></citetitle> <emphasis role="strong">21:</emphasis>350–382.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0049" role="bibliographyEntry">
            <para>49.<emphasis role="strong">Deback C, Fillet AM, Dhedin N, Barrou B, Varnous S, Najioullah F, Bricaire F, Agut H.</emphasis> 2007. Monitoring of human cytomegalovirus infection in immunosuppressed patients using real-time PCR on whole blood. <citetitle><emphasis>J Clin Virol</emphasis></citetitle> <emphasis role="strong">40:</emphasis>173–179.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0050" role="bibliographyEntry">
            <para>50.<emphasis role="strong">Hakim H, Gibson C, Pan J, Srivastava K, Gu Z, Bankowski MJ, Hayden RT.</emphasis> 2007. Comparison of various blood compartments and reporting units for the detection and quantification of Epstein-Barr virus in peripheral blood. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">45:</emphasis>2151–2155.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0051" role="bibliographyEntry">
            <para>51.<emphasis role="strong">Perlman J, Gibson C, Pounds SB, Gu Z, Bankowski MJ, Hayden RT.</emphasis> 2007. Quantitative real-time PCR detection of adenovirus in clinical blood specimens: a comparison of plasma, whole blood and peripheral blood mononuclear cells. <citetitle><emphasis>J Clin Virol</emphasis></citetitle> <emphasis role="strong">40:</emphasis>295–300.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0052" role="bibliographyEntry">
            <para>52.<emphasis role="strong">Ruf S, Behnke-Hall K, Gruhn B, Bauer J, Horn M, Beck J, Reiter A, Wagner HJ.</emphasis> 2012. Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation. <citetitle><emphasis>J Clin Virol</emphasis></citetitle> <emphasis role="strong">53:</emphasis>186–194.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0053" role="bibliographyEntry">
            <para>53.<emphasis role="strong">Griffith BP, Mayo DR.</emphasis> 2006. Increased levels of HIV RNA detected in samples with viral loads close to the detection limit collected in Plasma Preparation Tubes (PPT). <citetitle><emphasis>J Clin Virol</emphasis></citetitle> <emphasis role="strong">35:</emphasis>197–200.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0054" role="bibliographyEntry">
            <para>54.<emphasis role="strong">Rebeiro PF, Kheshti A, Bebawy SS, Stinnette SE, Erdem H, Tang YW, Sterling TR, Raffanti SP, D’Aquila RT.</emphasis> 2008. Increased detectability of plasma HIV-1 RNA after introduction of a new assay and altered specimen-processing procedures. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">47:</emphasis>1354–1357.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0055" role="bibliographyEntry">
            <para>55.<emphasis role="strong">Salimnia H, Moore EC, Crane LR, Macarthur RD, Fairfax MR.</emphasis> 2005. Discordance between viral loads determined by Roche COBAS AMPLICOR human immunodeficiency virus type 1 monitor (version 1.5) standard and ultrasensitive assays caused by freezing patient plasma in centrifuged Becton-Dickinson Vacutainer brand plasma preparation tubes. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>4635–4639.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0056" role="bibliographyEntry">
            <para>56.<emphasis role="strong">Kran AM, Jonassen TO, Sannes M, Jakobsen K, Lind A, Maeland A, Holberg-Petersen M.</emphasis> 2009. Overestimation of human immunodeficiency virus type 1 load caused by the presence of cells in plasma from plasma preparation tubes. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>2170–2174.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0057" role="bibliographyEntry">
            <para>57.<emphasis role="strong">Wan H, Seth A, Rainen L, Fernandes H.</emphasis> 2010. Coamplification of HIV-1 proviral DNA and viral RNA in assays used for quantification of HIV-1 RNA. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>2186–2190.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0058" role="bibliographyEntry">
            <para>58.<emphasis role="strong">Fernandes H, Morosyuk S, Abravaya K, Ramanathan M, Rainen L.</emphasis> 2010. Evaluation of effect of specimen-handling parameters for plasma preparation tubes on viral load measurements obtained by using the Abbott RealTime HIV-1 load assay. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>2464–2468.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0059" role="bibliographyEntry">
            <para>59.<emphasis role="strong">Kraft CS, Binongo JNG, Burd EM, Eaton ME, McCloskey CB, Fernandes H, Hill CE, Caliendo AM.</emphasis> 2013. Successful use of Plasma Preparation Tubes™ (PPTs) in the COBAS<superscript>®</superscript> AmpliPrep/COBAS<superscript>®</superscript> TaqMan<superscript>®</superscript> HIV-1 test. <citetitle><emphasis>J Clin Virol</emphasis></citetitle> <emphasis role="strong">57:</emphasis>77–79.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0060" role="bibliographyEntry">
            <para>60.<emphasis role="strong">Grant PR, Kitchen A, Barbara JA, Hewitt P, Sims CM, Garson JA, Tedder RS.</emphasis> 2000. Effects of handling and storage of blood on the stability of hepatitis C virus RNA: implications for NAT testing in transfusion practice. <citetitle><emphasis>Vox Sang</emphasis></citetitle> <emphasis role="strong">78:</emphasis>137–142.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0061" role="bibliographyEntry">
            <para>61.<emphasis role="strong">Leland DS, Ginocchio CC.</emphasis> 2007. Role of cell culture for virus detection in the age of technology. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">20:</emphasis>49–78.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0062" role="bibliographyEntry">
            <para>62.<emphasis role="strong">St George K, Boyd MJ, Lipson SM, Ferguson D, Cartmell GF, Falk LH, Rinaldo CR, Landry ML.</emphasis> 2000. A multisite trial comparing two cytomegalovirus (CMV) pp65 antigenemia test kits, Biotest CMV Brite and Bartels/Argene CMV antigenemia. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">38:</emphasis>1430–1433.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0063" role="bibliographyEntry">
            <para>63.<emphasis role="strong">Buller RS, Bailey TC, Ettinger NA, Keener M, Langlois T, Miller JP, Storch GA.</emphasis> 1992. Use of a modified shell vial technique to quantitate cytomegalovirus viremia in a population of solid-organ transplant recipients. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">30:</emphasis>2620–2624.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0064" role="bibliographyEntry">
            <para>64.<emphasis role="strong">Lipson SM, Falk LH, Lee SH.</emphasis> 1996. Effect of leukocyte concentration and inoculum volume on the laboratory identification of cytomegalovirus in peripheral blood by the centrifugation culture-antigen detection methodology. <citetitle><emphasis>Arch Pathol Lab Med</emphasis></citetitle> <emphasis role="strong">120:</emphasis>53–56.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0065" role="bibliographyEntry">
            <para>65.<emphasis role="strong">Buller RS, Gaudreault-Keener M, Rossiter-Fornoff J, Storch GA.</emphasis> 1995. Direct quantitative comparison of shell vial and conventional culture for detection of CMV viremia. <citetitle><emphasis>Clin Diagn Virol</emphasis></citetitle> <emphasis role="strong">3:</emphasis>317–322.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0066" role="bibliographyEntry">
            <para>66.<emphasis role="strong">Florea AV, Ionescu DN, Melhem MF.</emphasis> 2007. Parvovirus B19 infection in the immunocompromised host. <citetitle><emphasis>Arch Pathol Lab Med</emphasis></citetitle> <emphasis role="strong">131:</emphasis>799–804.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0067" role="bibliographyEntry">
            <para>67.<emphasis role="strong">Maakaroun NR, Moanna A, Jacob JT, Albrecht H.</emphasis> 2010. Viral infections associated with haemophagocytic syndrome. <citetitle><emphasis>Rev Med Virol</emphasis></citetitle> <emphasis role="strong">20:</emphasis>93–105.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0068" role="bibliographyEntry">
            <para>68.<emphasis role="strong">Duong S, Dezube BJ, Desai G, Eichelberger K, Qian Q, Kirby JE.</emphasis> 2009. Limited utility of bone marrow culture: a ten-year retrospective analysis. <citetitle><emphasis>Lab Med</emphasis></citetitle> <emphasis role="strong">40:</emphasis>37–38.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0069" role="bibliographyEntry">
            <para>69.<emphasis role="strong">Phillips CF, Benyesh-Melnick M, Seidel EH, Fernbach DJ.</emphasis> 1965. Failure to isolate viral agents from bone marrows of children with acute leukemia. <citetitle><emphasis>BMJ</emphasis></citetitle> <emphasis role="strong">1:</emphasis>286–288.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0070" role="bibliographyEntry">
            <para>70.<emphasis role="strong">Akane A, Matsubara K, Nakamura H, Takahashi S, Kimura K.</emphasis> 1994. Identification of the heme compound copurified with deoxyribonucleic acid (DNA) from bloodstains, a major inhibitor of polymerase chain reaction (PCR) amplification. <citetitle><emphasis>J Forensic Sci</emphasis></citetitle> <emphasis role="strong">39:</emphasis>362–372.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0071" role="bibliographyEntry">
            <para>71.<emphasis role="strong">Greenfield L, White TJ.</emphasis> 1993. Sample preparation methods, p 122–137. <citetitle><emphasis>In</emphasis></citetitle> Persing DHST, Tenover FC, White TJ (ed), <citetitle><emphasis>Diagnostic Molecular Biology: Principles and Applications.</emphasis></citetitle> ASM Press, Washington, DC.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0072" role="bibliographyEntry">
            <para>72.<emphasis role="strong">Ratnamohan VM, Cunningham AL, Rawlinson WD.</emphasis> 1998. Removal of inhibitors of CSF-PCR to improve diagnosis of herpesviral encephalitis. <citetitle><emphasis>J Virol Methods</emphasis></citetitle> <emphasis role="strong">72:</emphasis>59–65.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0073" role="bibliographyEntry">
            <para>73.<emphasis role="strong">DeBiasi RL, Tyler KL.</emphasis> 2004. Molecular methods for diagnosis of viral encephalitis. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">17:</emphasis>903–925.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0074" role="bibliographyEntry">
            <para>74.<emphasis role="strong">Lakeman FD, Whitley RJ, National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.</emphasis> 1995. Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">171:</emphasis>857–863.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0075" role="bibliographyEntry">
            <para>75.<emphasis role="strong">Snijdewind IJ, van Kampen JJ, Fraaij PL, van der Ende ME, Osterhaus AD, Gruters RA.</emphasis> 2012. Current and future applications of dried blood spots in viral disease management. <citetitle><emphasis>Antiviral Res</emphasis></citetitle> <emphasis role="strong">93:</emphasis>309–321.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0076" role="bibliographyEntry">
            <para>76.<emphasis role="strong">Brambilla D, Jennings C, Aldrovandi G, Bremer J, Comeau AM, Cassol SA, Dickover R, Jackson JB, Pitt J, Sullivan JL, Butcher A, Grosso L, Reichelderfer P, Fiscus SA.</emphasis> 2003. Multicenter evaluation of use of dried blood and plasma spot specimens in quantitative assays for human immunodeficiency virus RNA: measurement, precision, and RNA stability. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">41:</emphasis>1888–1893.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0077" role="bibliographyEntry">
            <para>77.<emphasis role="strong">Limaye AP, Santo Hayes TK, Huang ML, Magaret A, Boeckh M, Jerome KR.</emphasis> 2013. Quantitation of cytomegalovirus DNA load in dried blood spots correlates well with plasma viral load. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>2360–2364.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0078" role="bibliographyEntry">
            <para>78.<emphasis role="strong">Sambursky R, Trattler W, Tauber S, Starr C, Friedberg M, Boland T, McDonald M, DellaVecchia M, Luchs J.</emphasis> 2013. Sensitivity and specificity of the AdenoPlus test for diagnosing adenoviral conjunctivitis. <citetitle><emphasis>JAMA Ophthalmol</emphasis></citetitle> <emphasis role="strong">131:</emphasis>17–22.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0079" role="bibliographyEntry">
            <para>79.<emphasis role="strong">Wiedbrauk DL, Werner JC, Drevon AM.</emphasis> 1995. Inhibition of PCR by aqueous and vitreous fluids. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">33:</emphasis>2643–2646.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0080" role="bibliographyEntry">
            <para>80.<emphasis role="strong">Darlin L, Borgfeldt C, Forslund O, Hénic E, Dillner J, Kannisto P.</emphasis> 2013. Vaginal self-sampling without preservative for human papillomavirus testing shows good sensitivity. <citetitle><emphasis>J Clin Virol</emphasis></citetitle> <emphasis role="strong">56:</emphasis>52–56.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0081" role="bibliographyEntry">
            <para>81.<emphasis role="strong">Gage JC, Partridge EE, Rausa A, Gravitt PE, Wacholder S, Schiffman M, Scarinci I, Castle PE.</emphasis> 2011. Comparative performance of human papillomavirus DNA testing using novel sample collection methods. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>4185–4189.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0082" role="bibliographyEntry">
            <para>82.<emphasis role="strong">Gök M, Heideman DA, van Kemenade FJ, Berkhof J, Rozendaal L, Spruyt JWM, Voorhorst F, Beliën JAM, Babovic M, Snijders PJF, Meijer CJ.</emphasis> 2010. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. <citetitle><emphasis>BMJ</emphasis></citetitle> <emphasis role="strong">340</emphasis>(mar11 1)<emphasis role="strong">:</emphasis>c1040.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0083" role="bibliographyEntry">
            <para>83.<emphasis role="strong">Petignat P, Faltin DL, Bruchim I, Tramèr MR, Franco EL, Coutlée F.</emphasis> 2007. Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. <citetitle><emphasis>Gynecol Oncol</emphasis></citetitle> <emphasis role="strong">105:</emphasis>530–535.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0084" role="bibliographyEntry">
            <para>84.<emphasis role="strong">Hernandez BY, Wilkens LR, Unger ER, Steinau M, Markowitz L, Garvin K, Thompson PJ, Shvetsov YB, O’Dillon K, Dunne EF.</emphasis> 2013. Evaluation of genital self-sampling methods for HPV detection in males. <citetitle><emphasis>J Clin Virol</emphasis></citetitle> <emphasis role="strong">58:</emphasis>168–175.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0085" role="bibliographyEntry">
            <para>85.<emphasis role="strong">Ogilvie GS, Taylor DL, Achen M, Cook D, Krajden M.</emphasis> 2009. Self-collection of genital human papillomavirus specimens in heterosexual men. <citetitle><emphasis>Sex Transm Infect</emphasis></citetitle> <emphasis role="strong">85:</emphasis>221–225.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0086" role="bibliographyEntry">
            <para>86.<emphasis role="strong">Etienney I, Vuong S, Si-Mohamed A, Fléjou JF, Atienza P, Bauer P, Cytological Diaconesses Group.</emphasis> 2012. Value of cytologic Papanicolaou smears and polymerase chain reaction screening for human papillomavirus DNA in detecting anal intraepithelial neoplasia: comparison with histology of a surgical sample. <citetitle><emphasis>Cancer</emphasis></citetitle> <emphasis role="strong">118:</emphasis>6031–6038.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0087" role="bibliographyEntry">
            <para>87.<emphasis role="strong">Goldstone SE, Lowe B, Rothmann T, Nazarenko I.</emphasis> 2012. Evaluation of the hybrid capture 2 assay for detecting anal high-grade dysplasia. <citetitle><emphasis>Int J Cancer</emphasis></citetitle> <emphasis role="strong">131:</emphasis>1641–1648.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0088" role="bibliographyEntry">
            <para>88.<emphasis role="strong">Boppana SB, Ross SA, Shimamura M, Palmer AL, Ahmed A, Michaels MG, Sánchez PJ, Bernstein DI, Tolan RW Jr, Novak Z, Chowdhury N, Britt WJ, Fowler KB, National Institute on Deafness and Other Communication Disorders CHIMES Study.</emphasis> 2011. Saliva polymerase-chain-reaction assay for cytomegalovirus screening in newborns. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">364:</emphasis>2111–2118.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0089" role="bibliographyEntry">
            <para>89.<emphasis role="strong">Hindiyeh MY, Aboudy Y, Wohoush M, Shulman LM, Ram D, Levin T, Frank T, Riccardo F, Khalili M, Sawalha ES, Obeidi M, Sabatinelli G, Grossman Z, Mendelson E.</emphasis> 2009. Characterization of large mumps outbreak among vaccinated Palestinian refugees. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>560–565.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0090" role="bibliographyEntry">
            <para>90.<emphasis role="strong">Holm-Hansen C, Tong G, Davis C, Abrams WR, Malamud D.</emphasis> 2004. Comparison of oral fluid collectors for use in a rapid point-of-care diagnostic device. <citetitle><emphasis>Clin Diagn Lab Immunol</emphasis></citetitle> <emphasis role="strong">11:</emphasis>909–912.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0091" role="bibliographyEntry">
            <para>91.<emphasis role="strong">Abernathy E, Cabezas C, Sun H, Zheng Q, Chen MH, Castillo-Solorzano C, Ortiz AC, Osores F, Oliveira L, Whittembury A, Andrus JK, Helfand RF, Icenogle J.</emphasis> 2009. Confirmation of rubella within 4 days of rash onset: comparison of rubella virus RNA detection in oral fluid with immunoglobulin M detection in serum or oral fluid. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>182–188.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0092" role="bibliographyEntry">
            <para>92.<emphasis role="strong">Hodinka RL, Nagashunmugam T, Malamud D.</emphasis> 1998. Detection of human immunodeficiency virus antibodies in oral fluids. <citetitle><emphasis>Clin Diagn Lab Immunol</emphasis></citetitle> <emphasis role="strong">5:</emphasis>419–426.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0093" role="bibliographyEntry">
            <para>93.<emphasis role="strong">Warrener L, Slibinskas R, Chua KB, Nigatu W, Brown KE, Sasnauskas K, Samuel D, Brown D.</emphasis> 2011. A point-of-care test for measles diagnosis: detection of measles-specific IgM antibodies and viral nucleic acid. <citetitle><emphasis>Bull World Health Organ</emphasis></citetitle> <emphasis role="strong">89:</emphasis>675–682.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0094" role="bibliographyEntry">
            <para>94.<emphasis role="strong">Lee SR, Kardos KW, Schiff E, Berne CA, Mounzer K, Banks AT, Tatum HA, Friel TJ, Demicco MP, Lee WM, Eder SE, Monto A, Yearwood GD, Guillon GB, Kurtz LA, Fischl M, Unangst JL, Kriebel L, Feiss G, Roehler M.</emphasis> 2011. Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid. <citetitle><emphasis>J Virol Methods</emphasis></citetitle> <emphasis role="strong">172:</emphasis>27–31.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0095" role="bibliographyEntry">
            <para>95.<emphasis role="strong">Pant Pai N, Balram B, Shivkumar S, Martinez-Cajas JL, Claessens C, Lambert G, Peeling RW, Joseph L.</emphasis> 2012. Head-to-head comparison of accuracy of a rapid point-of-care HIV test with oral versus whole-blood specimens: a systematic review and meta-analysis. <citetitle><emphasis>Lancet Infect Dis</emphasis></citetitle> <emphasis role="strong">12:</emphasis>373–380.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0096" role="bibliographyEntry">
            <para>96.<emphasis role="strong">Ross SA, Ahmed A, Palmer AL, Michaels MG, Sánchez PJ, Bernstein DI, Tolan RW Jr, Novak Z, Chowdhury N, Fowler KB, Boppana SB, National Institute on Deafness and Other Communication Disorders CHIMES Study.</emphasis> 2014. Detection of congenital cytomegalovirus infection by real-time polymerase chain reaction analysis of saliva or urine specimens. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">210:</emphasis>1415–1418.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0097" role="bibliographyEntry">
            <para>97.<emphasis role="strong">Lee RA, Herigon JC, Benedetti A, Pollock NR, Denkinger CM.</emphasis> 2021. Performance of saliva, oropharyngeal swabs, and nasal swabs for SARS-CoV-2 molecular detection: a systematic review and meta-analysis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">59:</emphasis>e02882–e20.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0098" role="bibliographyEntry">
            <para>98.<emphasis role="strong">Ginocchio CC, McAdam AJ.</emphasis> 2011. Current best practices for respiratory virus testing. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49</emphasis>(Suppl)<emphasis role="strong">:</emphasis>S44–S48.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0099" role="bibliographyEntry">
            <para>99.<emphasis role="strong">Zhou Y, O’Leary TJ.</emphasis> 2021. Relative sensitivity of anterior nares and nasopharyngeal swabs for initial detection of SARS-CoV-2 in ambulatory patients: rapid review and meta-analysis. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">16:</emphasis>e0254559.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0100" role="bibliographyEntry">
            <para>100.<emphasis role="strong">Spyridaki IS, Christodoulou I, de Beer L, Hovland V, Kurowski M, Olszewska-Ziaber A, Carlsen KH, Lødrup-Carlsen K, van Drunen CM, Kowalski ML, Molenkamp R, Papadopoulos NG.</emphasis> 2009. Comparison of four nasal sampling methods for the detection of viral pathogens by RT-PCR-A GA(<link linkend="ch0101s0014s0003li0002">2</link>)LEN project. <citetitle><emphasis>J Virol Methods</emphasis></citetitle> <emphasis role="strong">156:</emphasis>102–106.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0101" role="bibliographyEntry">
            <para>101.<emphasis role="strong">Abu-Diab A, Azzeh M, Ghneim R, Ghneim R, Zoughbi M, Turkuman S, Rishmawi N, Issa AE, Siriani I, Dauodi R, Kattan R, Hindiyeh MY.</emphasis> 2008. Comparison between pernasal flocked swabs and nasopharyngeal aspirates for detection of common respiratory viruses in samples from children. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">46:</emphasis>2414–2417.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0102" role="bibliographyEntry">
            <para>102.<emphasis role="strong">Daley P, Castriciano S, Chernesky M, Smieja M.</emphasis> 2006. Comparison of flocked and rayon swabs for collection of respiratory epithelial cells from uninfected volunteers and symptomatic patients. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">44:</emphasis>2265–2267.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0103" role="bibliographyEntry">
            <para>103.<emphasis role="strong">Faden H.</emphasis> 2010. Comparison of midturbinate flocked-swab specimens with nasopharyngeal aspirates for detection of respiratory viruses in children by the direct fluorescent antibody technique. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>3742–3743.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0104" role="bibliographyEntry">
            <para>104.<emphasis role="strong">Smieja M, Castriciano S, Carruthers S, So G, Chong S, Luinstra K, Mahony JB, Petrich A, Chernesky M, Savarese M, Triva D.</emphasis> 2010. Development and evaluation of a flocked nasal midturbinate swab for self-collection in respiratory virus infection diagnostic testing. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>3340–3342.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0105" role="bibliographyEntry">
            <para>105.<emphasis role="strong">Campbell AP, Kuypers J, Englund JA, Guthrie KA, Corey L, Boeckh M.</emphasis> 2013. Self-collection of foam nasal swabs for respiratory virus detection by PCR among immunocompetent subjects and hematopoietic cell transplant recipients. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>324–327.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0106" role="bibliographyEntry">
            <para>106.<emphasis role="strong">Scansen KA, Bonsu BK, Stoner E, Mack K, Salamon D, Leber A, Marcon MJ.</emphasis> 2010. Comparison of polyurethane foam to nylon flocked swabs for collection of secretions from the anterior nares in performance of a rapid influenza virus antigen test in a pediatric emergency department. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>852–856.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0107" role="bibliographyEntry">
            <para>107.<emphasis role="strong">Munywoki PK, Hamid F, Mutunga M, Welch S, Cane P, Nokes DJ.</emphasis> 2011. Improved detection of respiratory viruses in pediatric outpatients with acute respiratory illness by real-time PCR using nasopharyngeal flocked swabs. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>3365–3367.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0108" role="bibliographyEntry">
            <para>108.<emphasis role="strong">Walsh P, Overmyer CL, Pham K, Michaelson S, Gofman L, DeSalvia L, Tran T, Gonzalez D, Pusavat J, Feola M, Iacono KT, Mordechai E, Adelson ME.</emphasis> 2008. Comparison of respiratory virus detection rates for infants and toddlers by use of flocked swabs, saline aspirates, and saline aspirates mixed in universal transport medium for room temperature storage and shipping. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">46:</emphasis>2374–2376.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0109" role="bibliographyEntry">
            <para>109.<emphasis role="strong">Hammitt LL, Kazungu S, Welch S, Bett A, Onyango CO, Gunson RN, Scott JAG, Nokes DJ.</emphasis> 2011. Added value of an oropharyngeal swab in detection of viruses in children hospitalized with lower respiratory tract infection. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>2318–2320.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0110" role="bibliographyEntry">
            <para>110.<emphasis role="strong">Lieberman D, Lieberman D, Shimoni A, Keren-Naus A, Steinberg R, Shemer-Avni Y.</emphasis> 2010. Pooled nasopharyngeal and oropharyngeal samples for the identification of respiratory viruses in adults. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">29:</emphasis>733–735.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0111" role="bibliographyEntry">
            <para>111.<emphasis role="strong">Mulrennan S, Tempone SS, Ling IT, Williams SH, Gan GC, Murray RJ, Speers DJ.</emphasis> 2010. Pandemic influenza (H1N1) 2009 pneumonia: CURB-65 score for predicting severity and nasopharyngeal sampling for diagnosis are unreliable. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">5:</emphasis>e12849.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0112" role="bibliographyEntry">
            <para>112.<emphasis role="strong">Yeh E, Luo RF, Dyner L, Hong DK, Banaei N, Baron EJ, Pinsky BA.</emphasis> 2010. Preferential lower respiratory tract infection in swine-origin 2009 A(H1N1) influenza. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">50:</emphasis>391–394.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0113" role="bibliographyEntry">
            <para>113.<emphasis role="strong">Agrawal S, Goel AD, Gupta N, Gonuguntla HK, Colt H.</emphasis> 2022. A systematic review and metanalysis of diagnostic yield of BAL for detection of SARS-CoV-2. <citetitle><emphasis>Heart Lung</emphasis></citetitle> <emphasis role="strong">52:</emphasis>95–105.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0114" role="bibliographyEntry">
            <para>114.<emphasis role="strong">Chan JF, Lau SK, To KK, Cheng VC, Woo PC, Yuen KY.</emphasis> 2015. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">28:</emphasis>465–522.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0115" role="bibliographyEntry">
            <para>115.<emphasis role="strong">Loens K, Van Heirstraeten L, Malhotra-Kumar S, Goossens H, Ieven M.</emphasis> 2009. Optimal sampling sites and methods for detection of pathogens possibly causing community-acquired lower respiratory tract infections. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>21–31.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0116" role="bibliographyEntry">
            <para>116.<emphasis role="strong">Falsey AR, Formica MA, Walsh EE.</emphasis> 2012. Yield of sputum for viral detection by reverse transcriptase PCR in adults hospitalized with respiratory illness. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>21–24.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0117" role="bibliographyEntry">
            <para>117.<emphasis role="strong">Thea DM, Seidenberg P, Park DE, Mwananyanda L, Fu W, Shi Q, Baggett HC, Brooks WA, Feikin DR, Howie SRC, Knoll MD, Kotloff KL, Levine OS, Madhi SA, O’Brien KL, Scott JAG, Antonio M, Awori JO, Baillie VL, DeLuca AN, Driscoll AJ, Higdon MM, Hossain L, Jahan Y, Karron RA, Kazungu S, Li M, Moore DP, Morpeth SC, Ofordile O, Prosperi C, Sangwichian O, Sawatwong P, Sylla M, Tapia MD, Zeger SL, Murdoch DR, Hammitt LL, PERCH Study Group.</emphasis> 2017. Limited utility of polymerase chain reaction in induced sputum specimens for determining the causes of childhood pneumonia in resource-poor settings: findings from the Pneumonia Etiology for Child Health (PERCH) study. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">64</emphasis>(Suppl 3)<emphasis role="strong">:</emphasis>S289–S300.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0118" role="bibliographyEntry">
            <para>118.<emphasis role="strong">Landry ML, Ferguson D.</emphasis> 2010. Cytospin-enhanced immunofluorescence and impact of sample quality on detection of novel swine origin (H1N1) influenza virus. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>957–959.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0119" role="bibliographyEntry">
            <para>119.<emphasis role="strong">Drago F, Rampini P, Rampini E, Rebora A.</emphasis> 2002. Atypical exanthems: morphology and laboratory investigations may lead to an aetiological diagnosis in about 70% of cases. <citetitle><emphasis>Br J Dermatol</emphasis></citetitle> <emphasis role="strong">147:</emphasis>255–260.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0120" role="bibliographyEntry">
            <para>120.<emphasis role="strong">Rahman M, Goegebuer T, De Leener K, Maes P, Matthijnssens J, Podder G, Azim T, Van Ranst M.</emphasis> 2004. Chromatography paper strip method for collection, transportation, and storage of rotavirus RNA in stool samples. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">42:</emphasis>1605–1608.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0121" role="bibliographyEntry">
            <para>121.<emphasis role="strong">Wilson ML.</emphasis> 1996. General principles of specimen collection and transport. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">22:</emphasis>766–777.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0122" role="bibliographyEntry">
            <para>122.<emphasis role="strong">Mills AM, Guo FP, Copland AP, Pai RK, Pinsky BA.</emphasis> 2013. A comparison of CMV detection in gastrointestinal mucosal biopsies using immunohistochemistry and PCR performed on formalin-fixed, paraffin-embedded tissue. <citetitle><emphasis>Am J Surg Pathol</emphasis></citetitle> <emphasis role="strong">37:</emphasis>995–1000.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0123" role="bibliographyEntry">
            <para>123.<emphasis role="strong">Folkins AK, Chisholm KM, Guo FP, McDowell M, Aziz N, Pinsky BA.</emphasis> 2013. Diagnosis of congenital CMV using PCR performed on formalin-fixed, paraffin-embedded placental tissue. <citetitle><emphasis>Am J Surg Pathol</emphasis></citetitle> <emphasis role="strong">37:</emphasis>1413–1420.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0124" role="bibliographyEntry">
            <para>124.<emphasis role="strong">Reagan-Steiner S, Simeone R, Simon E, Bhatnagar J, Oduyebo T, Free R, Denison AM, Rabeneck DB, Ellington S, Petersen E, Gary J, Hale G, Keating MK, Martines RB, Muehlenbachs A, Ritter J, Lee E, Davidson A, Conners E, Scotland S, Sandhu K, Bingham A, Kassens E, Smith L, St George K, Ahmad N, Tanner M, Beavers S, Miers B, VanMaldeghem K, Khan S, Rabe I, Gould C, Meaney-Delman D, Honein MA, Shieh WJ, Jamieson DJ, Fischer M, Zaki SR, US Zika Pregnancy Registry Collaboration, Zika Virus Response Epidemiology and Surveillance Task Force Pathology Team.</emphasis> 2017. Evaluation of placental and fetal tissue specimens for Zika virus infection—50 states and District of Columbia, January–December, 2016. <citetitle><emphasis>MMWR Morb Mortal Wkly Rep</emphasis></citetitle> <emphasis role="strong">66:</emphasis>636–643.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0125" role="bibliographyEntry">
            <para>125.<emphasis role="strong">Tan SK, Sahoo MK, Milligan SB, Taylor N, Pinsky BA.</emphasis> 2017. Stability of Zika virus in urine: specimen processing considerations and implications for the detection of RNA targets in urine. <citetitle><emphasis>J Virol Methods</emphasis></citetitle> <emphasis role="strong">248:</emphasis>66–70.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0126" role="bibliographyEntry">
            <para>126.<emphasis role="strong">Behzadbehbahani A, Klapper PE, Vallely PJ, Cleator GM.</emphasis> 1997. Detection of BK virus in urine by polymerase chain reaction: a comparison of DNA extraction methods. <citetitle><emphasis>J Virol Methods</emphasis></citetitle> <emphasis role="strong">67:</emphasis>161–166.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0127" role="bibliographyEntry">
            <para>127.<emphasis role="strong">Khan G, Kangro HO, Coates PJ, Heath RB.</emphasis> 1991. Inhibitory effects of urine on the polymerase chain reaction for cytomegalovirus DNA. <citetitle><emphasis>J Clin Pathol</emphasis></citetitle> <emphasis role="strong">44:</emphasis>360–365.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0128" role="bibliographyEntry">
            <para>128.<emphasis role="strong">Tang YW, Sefers SE, Li H, Kohn DJ, Procop GW.</emphasis> 2005. Comparative evaluation of three commercial systems for nucleic acid extraction from urine specimens. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>4830–4833. (Correction.)</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0129" role="bibliographyEntry">
            <para>129.<emphasis role="strong">Forman M, Valsamakis A, Arav-Boger R.</emphasis> 2012. Dried urine spots for detection and quantification of cytomegalovirus in newborns. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">73:</emphasis>326–329.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0130" role="bibliographyEntry">
            <para>130.<emphasis role="strong">Koyano S, Inoue N, Oka A, Moriuchi H, Asano K, Ito Y, Yamada H, Yoshikawa T, Suzutani T, Japanese Congenital Cytomegalovirus Study Group.</emphasis> 2011. Screening for congenital cytomegalovirus infection using newborn urine samples collected on filter paper: feasibility and outcomes from a multicentre study. <citetitle><emphasis>BMJ Open</emphasis></citetitle> <emphasis role="strong">1:</emphasis>e000118.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0131" role="bibliographyEntry">
            <para>131.<emphasis role="strong">Nozawa N, Koyano S, Yamamoto Y, Inami Y, Kurane I, Inoue N.</emphasis> 2007. Real-time PCR assay using specimens on filter disks as a template for detection of cytomegalovirus in urine. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">45:</emphasis>1305–1307.</para>
          </listitem>
          <listitem id="ch0101s0014s0003li0132" role="bibliographyEntry">
            <para>132.<emphasis role="strong">International Air Transport Association.</emphasis> 2022. <citetitle><emphasis>Dangerous Goods Regulations.</emphasis></citetitle> International Air Transport Association, Montreal, Canada.</para>
          </listitem>
        </itemizedlist>
        <anchor id="ch0101s0014s0003a0004"/>
        <beginpage pagenum="1632"/>
        <anchor id="ch0101s0014s0003a0005"/>
        <beginpage pagenum="1634"/>
        <anchor id="ch0101s0014s0003a0006"/>
        <beginpage pagenum="1635"/>
      </sect2>
    </sect1>
  </chapter>
